var title_f28_51_29488="Rastelli classification of AV canal defects";
var content_f28_51_29488=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Rastelli classification of atrioventricular canal defects",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 208px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Rastelli type A: The most common type, in which the superior bridging leaflet is committed to the left ventricle&nbsp;with&nbsp;chordal attachments to the crest of the ventricular septum.",
"    <br>",
"     (B) Rastelli type B: The least common type, in which the superior bridging leaflet extends into the right ventricle.",
"     <br>",
"      (C) Rastelli type C: In this form, the superior bridging leaflet is even larger and has no chordal attachment to the interventricular septum, referred to as &ldquo;free floating.&rdquo; It is found in combination with other cardiac defects, such as tetralogy of Fallot, transposition of the great arteries, and heterotaxy syndromes.",
"      <div class=\"footnotes\">",
"       SB: superior bridging leaflet; AL: anterior leaflet; RLL: right lateral leaflet; IB: inferior bridging leaflet; LLL: left lateral leaflet.",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_51_29488=[""].join("\n");
var outline_f28_51_29488=null;
var title_f28_51_29489="Classification exercise";
var content_f28_51_29489=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Classification of sports",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 482px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This classification is based on peak static and dynamic components achieved during competition. It should be noted, however, that higher values may be reached during training. The increasing dynamic component is defined in terms of the estimated percent of maximal oxygen uptake (MaxO",
"    <sub>",
"     2",
"    </sub>",
"    ) achieved and results in an increasing cardiac output. The increasing static component is related to the estimated percent of maximal voluntary contraction (MVC) reached and results in an increasing blood pressure load. The lowest total cardiovascular demands (cardiac output and blood pressure) are shown in green and the highest in red. Blue, yellow, and orange depict low moderate, moderate, and high moderate total cardiovascular demands.",
"    <div class=\"footnotes\">",
"     * Danger of bodily collision.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Increased risk if syncope occurs.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mitchell JH, Haskell W, Snell P, Van Camp SP. Task Force 8: classification of sports. J Am Coll Cardiol 2005; 45:1364. Copyright &copy; 2005 American College of Cardiology Foundation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_51_29489=[""].join("\n");
var outline_f28_51_29489=null;
var title_f28_51_29490="Ureteral stent on plain abdominal radiography";
var content_f28_51_29490=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F64090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F64090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ureteral stent on plain abdominal radiography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 294px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ureteral stents are placed endoscopically over a guidewire into the ureter. The proximal and distal curls (ie, pigtails) become apparent when the guidewire is removed. Proper positioning is indicated by placement of the proximal curl in the renal pelvis and distal curl in the bladder.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_51_29490=[""].join("\n");
var outline_f28_51_29490=null;
var title_f28_51_29491="Clamping uteroovarian ligament";
var content_f28_51_29491=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 478px\">",
"   <div class=\"ttl\">",
"    Clamping of the utero-ovarian ligament during vaginal hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 458px; height: 393px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_51_29491=[""].join("\n");
var outline_f28_51_29491=null;
var title_f28_51_29492="Activated prothrombin complex concentrates (factor VIII inhibitor bypassing activity): Patient drug information";
var content_f28_51_29492=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Activated prothrombin complex concentrates (factor VIII inhibitor bypassing activity): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/61/37844?source=see_link\">",
"     see \"Activated prothrombin complex concentrates (factor VIII inhibitor bypassing activity): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/39/5748?source=see_link\">",
"     see \"Activated prothrombin complex concentrates (factor VIII inhibitor bypassing activity): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F135834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Feiba NF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F135835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Feiba NF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10025902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2723539",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause blood clots. Tell your doctor right away if you have chest pain, shortness of breath, eyesight problems, bad belly pain, or pain or swelling of the legs or arms.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hemophilia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691426",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat bleeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to anti-inhibitor coagulant complex or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to latex, talk with your doctor. Some products are found in latex.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703723",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have blood clots.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gallbladder disease, blood clots, heart attacks, and other blood vessel problems may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695961",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be given at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Most of the time, this drug will be given to you in a doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         If drug is given at home:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699567",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store unopened bottles at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11470 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-714CE7359B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_51_29492=[""].join("\n");
var outline_f28_51_29492=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135834\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135835\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025902\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025904\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025903\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025908\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025909\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025911\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025906\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025907\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025912\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025913\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/61/37844?source=related_link\">",
"      Activated prothrombin complex concentrates (factor VIII inhibitor bypassing activity): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/39/5748?source=related_link\">",
"      Activated prothrombin complex concentrates (factor VIII inhibitor bypassing activity): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_51_29493="Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine: Pediatric drug information";
var content_f28_51_29493=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?42/35/43574?source=see_link\">",
"    see \"Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/49/17169?source=see_link\">",
"    see \"Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3000502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gardasil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5994263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Gardasil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F3270170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F3270179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/35/43574?source=see_link\">",
"      see \"Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Immunization:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children (preadolescent) &ge;9 years, Adolescents, and Adults &le;26 years: Initial dose: I.M.: 0.5 mL followed by a second dose 2 months after first dose; third dose 6 months after first dose; immunization with HPV vaccine is usually initiated at 11-12 years; optimally, vaccination should be completed prior to onset of sexual activity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     CDC recommended immunization schedule: Administer first dose at age 11-12 years; begin series in females aged 13-26 years or males 13-21 years if not previously vaccinated. Males may also be vaccinated through 26 years of age. Minimum interval between first and second doses is 4 weeks; minimum interval between first and third doses is 24 weeks. Inadequate doses or doses received following a shorter than recommended dosing interval should be repeated. The HPV vaccine series should be completed with the same product whenever possible (CDC, 2007; CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3011343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gardasil&reg;: HPV 6 L1 protein 20 mcg, HPV 11 L1 protein 40 mcg, HPV 16 L1 protein 40 mcg, and HPV 18 L1 protein 20 mcg per 0.5 mL (0.5 mL) [contains aluminum, polysorbate 80; manufactured using",
"     <i>",
"      S. cerevisiae",
"     </i>",
"     (baker's yeast)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3000504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3270180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     I.M.: Shake suspension well prior to use; do not use suspension if it is discolored or contains particulate matter; do not dilute or mix with other vaccines. Administer I.M. into the deltoid region of the upper arm or in the higher anterolateral area of the thigh;",
"     <b>",
"      not for I.V., intradermal, or SubQ administration",
"     </b>",
"     . Adolescents and adults should be vaccinated while seated or lying down. U.S. law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person&rsquo;s name, title and address be entered into the patient&rsquo;s permanent medical record. Patients who develop syncope associated with tonic-clonic movements usually respond when maintained in a supine or Trendelenburg position.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F3270177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Protect from light. May be stored at temperatures &le;25&deg;C (&le;77&deg;F) for a total time of &le;72 hours.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3270171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prevention of cervical, vulvar, vaginal, and anal cancer caused by HPV types 16 and 18; genital warts caused by HPV types 6 and 11; cervical adenocarcinoma",
"     <i>",
"      in situ",
"     </i>",
"     ; and vulvar, vaginal, cervical, or anal intraepithelial neoplasia caused by HPV types 6, 11, 16, 18 (FDA approved in females ages &ge;9 years and &le;26 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Prevention of genital warts caused by HPV types 6 and 11; anal cancer caused by HPV types 16 and 18; and anal intraepithelial neoplasia caused by HPV types 6, 11, 16, and 18 (FDA approved in males ages &ge;9 years and &le;26 years)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for females and males 11-12 years of age; catch-up vaccination is recommended for females 13-26 years of age and males 13-21 years of age. Males 22-26 years may also be vaccinated. The ACIP also recommends routine vaccination for men who have sex with men (MSM) through 26 years of age (CDC, 2011). Vaccination is also recommended for immunocompromised persons or MSM through 26 years of age who were not previously vaccinated when they were younger. Although not specifically recommended for their profession, healthcare providers within the recommended age groups should also receive the HPV vaccine.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9518288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Papillomavirus vaccine types 6, 11, 16, 18 (Gardasil&reg;) may be confused with Papillomavirus vaccine types 16, 18 (Cervarix&reg;)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F3000558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever, headache, insomnia, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site: Bruising, erythema, hematoma, pain, pruritus, swelling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, toothache, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, nasal congestion, pharyngolaryngeal pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute disseminated encephalomyelitis, alopecia areata, anaphylactic/anaphylactoid reaction, appendicitis, arrhythmia, arthritis, asthma, autoimmune hemolytic anemia and other autoimmune diseases, bronchospasm, cellulitis, cerebrovascular accident, chills, DVT, fatigue, gastroenteritis, Guillain-Barr&eacute; syndrome, hypersensitivity reaction, hyper-/hypothyroidism, injection site joint movement impairment, ITP, JIA, lymphadenopathy, motor neuron disease, pancreatitis, paralysis, pelvic inflammatory disease, pulmonary embolus, RA, renal failure (acute), seizure, sepsis, syncope (may result in falls with injury or be associated with tonic-clonic movements), transverse myelitis, urticaria, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3270173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypersensitivity to human papillomavirus vaccine, yeast, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F3878293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Immunization should be delayed during the course of an acute severe febrile illness; may administer to patients with mild acute illness (with or without fever). Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy, including high-dose corticosteroids); may have a reduced response to vaccination and vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (CDC, 2011). In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use caution in patients with bleeding disorders such as hemophilia or thrombocytopenia or patients on anticoagulant therapy, due to an increased risk for bleeding following I.M. administration. Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3270174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Immediate treatment for anaphylactic reactions should be available during vaccine use. There is no evidence that individuals already infected with HPV will be protected against disease by the same HPV types after vaccination. Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Injection contains polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F3000561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3000509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3000510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Teratogenic effects were not observed in animal studies. In clinical trials, women who were found to be pregnant before the completion of the 3-dose regimen were instructed to defer any remaining dose until pregnancy resolution. Pregnancies detected within 30 days of vaccination had a higher rate of congenital anomalies (pyloric stenosis, congenital megacolon, congenital hydronephrosis, hip dysplasia, club foot) than the placebo group. Pregnancies with onset beyond 30 days of vaccination had a rate of congenital anomalies consistent with the general population. Overall, the type of teratogenic events were the same as those generally observed for this age group.  Administration of the vaccine in pregnancy is not recommended; until additional information is available, the vaccine series (or completion of the series) should be delayed until pregnancy is completed. Pregnancy testing is not required prior to administration of the vaccine (CDC, 2013).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;display:inline\">",
"     A registry has been established for women exposed to the HPV vaccine during pregnancy (1-800-986-8999).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5177947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3270178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Promotes immunity to human HPV types 6, 11, 16, and 18 by inducing the production of neutralizing antibodies to the virus types",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F3270182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/49/17169?source=see_link\">",
"      see \"Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     This vaccine does not substitute for regular, routine cervical cancer screening; the vaccine is not intended for the treatment of active genital warts or cervical cancer. This vaccine may be given during a minor illness, such as a cold or low-grade fever. Three doses will be required for effective immunity. Inform prescriber immediately if difficulty breathing, chest pain, acute headache, rash, difficulty swallowing, or excessive pain/swelling at injection site occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10278556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;display:inline\">",
"     In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single visit, unless contraindications exist. If available, the use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events. If separate vaccines being used, evaluate product information regarding same syringe compatibility of vaccines. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of specific vaccine in a series come from the same manufacturer if possible (CDC, 2011). HPV vaccine may be administered concomitantly with Recombivax HB&reg; or with Menactra&reg; and Adacel&reg; (Reisinger, 2010).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For additional information, please refer to the following website:",
"     <a href=\"file://www.cdc.gov/vaccines/vpd-vac/\" target=\"_blank\">",
"      file://www.cdc.gov/vaccines/vpd-vac/",
"     </a>",
"     .",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      AAP Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, \"Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/51/29493/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Block SL, Nolan T, Sattler C, et al, &ldquo;Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 118(5):2135-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/51/29493/abstract-text/17079588/pubmed\" id=\"17079588\" target=\"_blank\">",
"        17079588",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males--Advisory Committee on Immunization Practices (ACIP), 2011,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2011, 60(50):1705-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/51/29493/abstract-text/22189893/pubmed\" id=\"22189893\" target=\"_blank\">",
"        22189893",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Quadrivalent Human Papillomavirus Vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2007, 56(RR-2):1-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/51/29493/abstract-text/17380109/pubmed\" id=\"17380109\" target=\"_blank\">",
"        17380109",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Syncope After Vaccination-United States, January 2005-July 2007,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 2;57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/51/29493/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Center for Immunization and Respiratory Diseases, \"General Recommendations on Immunization - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/51/29493/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, \"Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/51/29493/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reisinger KS, Block SL, Collins-Ogle M, et al, \"Safety, Tolerability, and Immunogenicity of Gardasil Given Concomitantly With Menactra and Adacel,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 125(6):1142-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/51/29493/abstract-text/20439595/pubmed\" id=\"20439595\" target=\"_blank\">",
"        20439595",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12994 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-5846377118-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_51_29493=[""].join("\n");
var outline_f28_51_29493=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000502\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5994263\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3270170\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3270179\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3011343\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000504\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3270180\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3270177\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3270171\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9518288\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000558\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3270173\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3878293\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3270174\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299822\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000561\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000509\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000510\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5177947\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3270178\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3270182\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10278556\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12994\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12994|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/35/43574?source=related_link\">",
"      Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/49/17169?source=related_link\">",
"      Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_51_29494="Umbilical cord prolapse";
var content_f28_51_29494=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Umbilical cord prolapse",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/51/29494/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/51/29494/contributors\">",
"     Melissa Bush, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/51/29494/contributors\">",
"     Keith Eddleman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/51/29494/contributors\">",
"     Victoria Belogolovkin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/51/29494/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/51/29494/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/51/29494/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/51/29494/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/51/29494/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Umbilical cord prolapse is a rare obstetrical emergency that occurs when the umbilical cord descends alongside or beyond the fetal presenting part. It is life-threatening to the fetus since blood flow through the umbilical vessels is usually compromised from compression of the cord between the fetus and the uterus, cervix, or pelvic inlet. There are two types of cord prolapse:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overt prolapse, which is the most common, refers to protrusion of the cord in advance of the fetal presenting part, often through the cervical os and into or beyond the vagina. The fetal membranes are invariably ruptured in these cases and the cord is visible or palpable on examination.",
"     </li>",
"     <li>",
"      Occult prolapse occurs when the cord descends alongside, but not past, the presenting part. It can occur with intact or ruptured membranes. The diagnosis should be considered in the differential diagnosis of a sudden, prolonged fetal heart rate deceleration. An occult prolapse often cannot be diagnosed with certainty, but is suggested by clinical features (eg, fetal bradycardia) and findings at cesarean delivery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cord prolapse occurs in 0.14 to 0.62 percent of deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/1\">",
"     1",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS AND ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy characteristics that increase the risk of cord prolapse are generally not modifiable, but awareness of patients at high risk may help facilitate prompt diagnosis and delivery when prolapse occurs. The two major etiologic categories of cord prolapse are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fetomaternal factors that lead to inadequate filling of the maternal pelvis by the fetus",
"     </li>",
"     <li>",
"      Iatrogenic obstetrical interventions",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fetomaternal factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors associated with cord prolapse that are nonmodifiable are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef54802 \" href=\"UTD.htm?9/16/9483\">",
"     table 1",
"    </a>",
"    ). Selected risk factors are briefly discussed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Fetal malpresentation",
"      </strong>",
"      &mdash; Nonvertex fetal presentation is consistently associated with a high risk of cord prolapse [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/1-4\">",
"       1-4",
"      </a>",
"      ]. In one review, the overall frequency of cord prolapse in vertex, breech, and transverse lies was 0.24, 3.5, and 9.6 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/2\">",
"       2",
"      </a>",
"      ]. Footling breech presentation carries a higher risk of cord prolapse than other types of breech presentation. Nevertheless, most cord prolapses occur with vertex presentations because of the relatively low incidence of noncephalic presentation.",
"     </li>",
"     <li>",
"      <strong>",
"       Prematurity",
"      </strong>",
"      &mdash; Infants delivering prematurely have a higher rate of cord prolapse, probably due to the smaller size of the fetus relative to the amniotic fluid volume and the increased frequency of malpresentation among premature fetuses [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/1,3,5\">",
"       1,3,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Multiple gestation",
"      </strong>",
"      &mdash; The risk of cord prolapse in a term twin pregnancy is confined to the second born twin, in whom there is an increased probability of malpresentation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/1,5-7\">",
"       1,5-7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Multiparity",
"      </strong>",
"      &mdash; Cord prolapse in multiparous women may be related to the increased likelihood of rupture of membranes prior to engagement of the presenting part, since engagement in multiparas often occurs after labor has begun and later than in nulliparas [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/4\">",
"       4",
"      </a>",
"      ]. A study of 30 patients with cord prolapse reported that two-thirds of the women were para six or more; one patient experienced cord prolapse in two successive deliveries [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Rupture of membranes",
"      </strong>",
"      &mdash; Iatrogenic or spontaneous rupture of membranes can lead to cord prolapse because a forceful gush of fluid may carry the cord beyond the presenting fetal part. The highest risk of this occurrence is with preterm premature rupture of membranes, polyhydramnios, or an unengaged fetal presenting part.",
"     </li>",
"     <li>",
"      <strong>",
"       Polyhydramnios",
"      </strong>",
"      &mdash; Polyhydramnios is often associated with an unstable lie or unengaged presenting part, as well as copious flow of amniotic fluid after membrane rupture [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/9\">",
"       9",
"      </a>",
"      ]. As discussed above, all of these factors increase the risk of cord prolapse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Iatrogenic obstetrical intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence that iatrogenic obstetrical intervention causes cord prolapse is conflicting and it is often difficult to determine whether cord prolapse would have occurred spontaneously if the intervention had not been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/10\">",
"     10",
"    </a>",
"    ]. The purported mechanism for cord prolapse in this setting is that disengagement of the fetal head during the intervention and a high outward flow of amniotic fluid allow the umbilical cord to be carried into the birth canal.",
"   </p>",
"   <p>",
"    Interventions that may predispose to cord prolapse include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Iatrogenic rupture of membranes",
"     </li>",
"     <li>",
"      Application of an internal scalp electrode",
"     </li>",
"     <li>",
"      Insertion of an intrauterine pressure catheter",
"     </li>",
"     <li>",
"      Manual rotation of the fetal head",
"     </li>",
"     <li>",
"      Amnioinfusion or amnioreduction",
"     </li>",
"     <li>",
"      External cephalic version in patients with ruptured membranes [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Application of forceps or vacuum",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some of these interventions are more commonly performed during labor induction; therefore, not unexpectedly, cord prolapse has been reported to occur more commonly with induced than spontaneous labor [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first sign of cord prolapse is usually a severe, prolonged fetal bradycardia or moderate to severe variable decelerations after a previously normal tracing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]. Cord prolapse should always be suspected where the abnormal fetal heart rate pattern develops soon after membrane rupture.",
"   </p>",
"   <p>",
"    The cord is palpable upon vaginal examination if there is overt prolapse, but it may not be readily identified if the prolapse is occult, particularly when membranes are intact. Less commonly, the patient may see or feel an overt cord prolapse or the care provider may initially palpate a pulsating cord on a vaginal examination performed to assess labor progress.",
"   </p>",
"   <p>",
"    If cord prolapse is not overt, the suspected diagnosis cannot be confirmed until a cesarean delivery is performed, and may not be apparent even at surgery.",
"   </p>",
"   <p>",
"    In one large series, mean cervical dilatation at the time of cord prolapse was 5.8 cm, but prolapse can occur at any cervical dilation from minimal to full dilatation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/10\">",
"     10",
"    </a>",
"    ]. The mean station in this series was -1.6, which is expected since an engaged presenting part generally prevents the cord from prolapsing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of fetal bradycardia of abrupt onset following a normal tracing include maternal hypotension, placental abruption, uterine rupture, and vasa previa. Fetal bradycardia following injection of an epidural anesthetic suggests maternal hypotension from vasodilatation; this usually responds to intravenous fluid infusion and ephedrine. In contrast to cord prolapse, placental abruption, uterine rupture, and vasa previa are usually accompanied by vaginal bleeding, and abruption and rupture are often painful in the absence of labor anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal obstetrical management of cord prolapse is prompt delivery to avoid fetal compromise or death from compression of the cord between the presenting fetal part and the margin of the pelvic inlet. Although immediate cesarean birth is generally the optimal mode of delivery, vaginal delivery may be considered in select situations",
"   </p>",
"   <p>",
"    There are no data from prospective or randomized studies on which to base management recommendations because of the infrequent and urgent nature of this problem. There are sparse data regarding attempted vaginal delivery in the setting of cord prolapse. Successful operative vaginal delivery with vacuum or forceps has been reported when cesarean delivery could not be performed immediately. One series of 93 cases of cord prolapse from a single center noted successful vaginal delivery in one third [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/14\">",
"     14",
"    </a>",
"    ]. Vaginal delivery was most likely in patients at full dilation with breech presentation or undergoing birth of the second twin at the time of the event. The event to delivery time interval was significantly faster in patients who underwent cesarean delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1942694\">",
"    <span class=\"h2\">",
"     Intrauterine resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following preoperative maneuvers can be helpful for reducing pressure on the cord. In the absence of comparative studies, there is no evidence that one maneuver is better than another.",
"   </p>",
"   <p>",
"    Manipulation of the cord and exposure to a cool environment may exacerbate poor perfusion by inducing spasm of the cord vessels, so these factors should be minimized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Funic decompression",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is the most common method of alleviating cord compression, and the maneuver we prefer. After diagnosis of cord prolapse, the examiner's hand is placed in the vagina and used to elevate the fetal head off of the cord while preparations for an emergency cesarean delivery are made. The patient can be placed in steep Trendelenburg or the knee-chest position to try to move the fetus and further alleviate cord occlusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1942733\">",
"    <span class=\"h3\">",
"     Bladder filling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another temporizing technique involves placing the patient in Trendelenburg position and inserting a Foley catheter into the bladder; the bladder is then rapidly filled with 500 to 700 milliliters of normal saline. The distended bladder elevates the presenting part and keeps it off of the cord, thus relieving the compression and potentially obviating the need for prolonged vaginal digital decompression. Bladder filling may be particularly useful when immediate cesarean delivery is not possible.",
"   </p>",
"   <p>",
"    One series of 51 cases employed both a tocolytic (ritodrine) and bladder filling to relieve cord compression [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/15\">",
"     15",
"    </a>",
"    ]. The mean interval from diagnosis to delivery was 35 minutes and there were no fetal or neonatal deaths; the majority of infants had Apgar scores &ge;7 at five minutes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Funic reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Funic reduction is a controversial approach to the management of cord prolapse. As with decompression, it is employed to alleviate pressure on the cord from the presenting part while preparations for cesarean delivery are being made. The procedure involves elevating the fetal head with gentle suprapubic pressure or transvaginally or both and then sliding the cord over the widest part of the vertex and placing it in the nuchal area. Gentle suprapubic fixation of the head decreases the chance of creating an oblique or transverse lie.",
"   </p>",
"   <p>",
"    Funic reduction had been considered an appropriate initial step in management of cord prolapse, but was subsequently discarded in favor of cesarean delivery because the procedure appeared to be associated with an increase in intrapartum asphyxia and demise [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/16\">",
"     16",
"    </a>",
"    ]. However, this association was observed prior to the advent of continuous fetal monitoring. With use of continuous fetal monitoring, this technique may permit vaginal delivery and avoid emergent cesarean delivery in some patients. This was suggested by a small series of eight patients with cord prolapse in which five vaginal deliveries were achieved 14 to 512 minutes after a successful funic reduction without anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/16\">",
"     16",
"    </a>",
"    ]. The other three patients either delivered vaginally shortly after the diagnosis of cord prolapse or were delivered by cesarean. All of the fetuses were in vertex presentation and had less than 25 cm of cord prolapsing. No morbidity or mortality was reported. Thus, funic reduction in the setting of continuous fetal monitoring appears to be a reasonable approach if vaginal delivery is imminent or if cesarean delivery cannot be performed immediately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Good neonatal outcomes have been reported in the majority of patients with cord prolapse [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/7,15,17\">",
"     7,15,17",
"    </a>",
"    ]. Perinatal mortality related to cord prolapse, which was as high as 375 per 1000 births in the early 1900s, has fallen to between 36 and 162 per 1000 births within the past few decades [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/18\">",
"     18",
"    </a>",
"    ]. This decline is likely secondary to the widespread availability of immediate delivery by cesarean birth when cord prolapse is diagnosed and significant improvements in neonatal intensive care.",
"   </p>",
"   <p>",
"    The interval between cord prolapse and delivery is a major determining factor in the immediate neonatal outcome and perinatal mortality, but not the only factor. Team training can significantly lower the time from diagnosis to delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple studies have evaluated the effect of diagnosis-to-delivery time on fetal outcome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the largest retrospective analyses of cord prolapse (n = 132 cases) found that the diagnosis-to-delivery interval had little influence on Apgar scores at 1 and 5 minutes if delivery occurred within 30 minutes [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/5\">",
"       5",
"      </a>",
"      ]. However, the incidence of acidemia (pH&le;7.1) increased after 10 minutes. There were 12 perinatal deaths, but only one of these deaths was attributed to birth asphyxia and occurred after a 100-minute diagnosis-to-delivery interval. The other 11 deaths were due to a variety of causes including extreme prematurity, lethal congenital anomalies, and placental abruption, and all but one occurred after a prolonged diagnosis-to-delivery interval (20 to 750 minutes).",
"     </li>",
"     <li>",
"      In another series of 65 cases of cord prolapse, there were five asphyxiated neonates and all five had diagnosis-to-delivery times that were shorter than the mean for the entire group (11 versus 20 minutes) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third series of 13 patients with cord prolapse occurring in the setting of preterm premature rupture of membranes noted",
"      <span class=\"nowrap\">",
"       9/13",
"      </span>",
"      cases were associated with a delayed diagnosis-to-delivery interval (over 60 minutes), but no neonate was acidemic (pH&le;7.1) at delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On the other hand, cord prolapse occurring outside of the hospital clearly has a poor prognosis. A series of 77 cases of cord prolapse reported",
"      <span class=\"nowrap\">",
"       3/7",
"      </span>",
"      occurrences before hospital admission resulted in",
"      <span class=\"nowrap\">",
"       fetal/neonatal",
"      </span>",
"      death compared to no deaths among the 70 in-hospital cases [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/4\">",
"       4",
"      </a>",
"      ]. The in-hospital cases had a mean diagnosis-to-delivery interval of 16 min (range 8 to 35 min).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The variability in the data cited above suggests that it is not simply the diagnosis-to-delivery interval that affects fetal outcome; the degree of cord compression also appears to be an important factor [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/7\">",
"     7",
"    </a>",
"    ]. This hypothesis is supported by rare case reports where prolonged cord prolapse has been managed expectantly. In one such report, a patient with overt cord prolapse diagnosed at 23 and",
"    <span class=\"nowrap\">",
"     2/7",
"    </span>",
"    weeks was managed expectantly for four days due to extreme prematurity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/21\">",
"     21",
"    </a>",
"    ]. The fetus was delivered when severe variable decelerations developed and survived, neurologically intact at eight months follow-up.",
"   </p>",
"   <p>",
"    The degree and duration of cord compression may actually be less than that predicted by simply measuring the time interval from diagnosis-to-delivery. Time spent resuscitating the fetus in utero (eg, by maternal position changes, bladder distention, or tocolysis) while preparations for cesarean delivery are being made might benefit the fetus, as reflected by higher Apgar scores and a lower incidence of neonatal asphyxia. In addition, some cords (eg, noncoiled) may be more vulnerable to cord compression than others. Prematurity, a risk factor for cord prolapse, is a major contributing factor to perinatal morbidity and mortality, thus gestational age should be taken into account when citing the relative risk of",
"    <span class=\"nowrap\">",
"     mortality/morbidity.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40840?source=see_link&amp;anchor=H6#H6\">",
"     \"Gross examination of the placenta\", section on 'Coiling'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are sparse data on the long-term outcome of children whose birth was complicated by cord prolapse. In the large series of 132 cases of cord prolapse discussed above, only 1 of 120 survivors had a long-term handicap [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/5\">",
"     5",
"    </a>",
"    ]. A study that looked at risk factors for cerebral palsy identified 110 children with cerebral palsy among 16,785 cases of cord prolapse (1 in 153 cord prolapses) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with prematurely ruptured membranes and malpresentation are at particular risk of prolapse and should be closely monitored. Options include checking for fetal heart rate decelerations with continuous fetal heart rate monitoring when the patient is on the labor unit and intermittent fetal heart rate monitoring and educating the patient regarding the signs and symptoms of cord prolapse in other settings.",
"   </p>",
"   <p>",
"    Identifying patients at risk for cord prolapse and avoiding unnecessary obstetric interventions in these patients may prevent some cases of prolapse. However, obstetric interventions are often indicated and cannot be avoided. Anticipation of prolapse and modification in standard techniques can reduce the risk of prolapse in these cases. If possible, amniotomy should be performed only when the fetal vertex is well applied to the cervix. When amniotomy is necessary and the fetal vertex is not well applied, controlled amniotomy with either a fetal scalp electrode or small gauge needle and simultaneous application of fundal pressure may decrease the risk of prolapse. We suggest using a small gauge needle to puncture fetal membranes in one or more places in the operating room when there is hydramnios or an unengaged fetal presenting part. This \"controlled amniotomy\" minimizes the risk of gushing amniotic fluid and enables emergency cesarean delivery in the event of cord prolapse.",
"   </p>",
"   <p>",
"    The clinician should try to avoid disengaging the fetal presenting part when performing procedures such as application of a fetal internal scalp electrode, intrauterine pressure catheter insertion, fetal scalp sampling, amnioinfusion, forceps application, and manual rotation of the fetal head.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H496167\">",
"    <span class=\"h2\">",
"     Pregnancies with funic presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not suggest routine sonography to assess umbilical cord position. However, ultrasound examination can be used to confirm cord position when there is a clinical suspicion of funic presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Color flow Doppler studies can clarify cord position if there is uncertainty on real-time sonographic examination (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65216 graphicRef79970 graphicRef59220 \" href=\"UTD.htm?34/58/35754\">",
"     image 1A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When funic presentation is identified as an incidental finding antepartum, we suggest follow-up evaluation of cord location to decide on the mode of delivery. In a series of 13 patients initially identified as having cord presentation on ultrasound, three had persistent sonographic evidence of cord presentation on follow-up and were delivered by cesarean birth, one following cord prolapse [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29494/abstract/26\">",
"     26",
"    </a>",
"    ]. The other four fetuses spontaneously converted to vertex with resolution of cord presentation. There are inadequate data to recommend for or against routine scheduled cesarean delivery if funic presentation is noted at term. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Umbilical cord prolapse is a rare event potentially associated with serious",
"      <span class=\"nowrap\">",
"       fetal/neonatal",
"      </span>",
"      complications. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for cord prolapse include (1) fetomaternal factors that lead to inadequate filling of the maternal pelvis by the fetus and (2) iatrogenic obstetrical interventions, but many prolapses occur without antecedent risk factors. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors and etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The first sign of cord prolapse is usually a severe, prolonged fetal bradycardia or moderate to severe variable decelerations after a previously normal tracing. The prolapse may be overt or occult. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In high risk patients, the risk of cord prolapse may be reduced by avoiding unnecessary obstetrical interventions, controlled amniotomy, and avoiding disengagement of the fetal head. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard obstetrical management of cord prolapse is prompt cesarean delivery to avoid fetal compromise or death from compression of the cord. However, vaginal delivery may be a reasonable option in select cases when delivery is imminent. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intrauterine resuscitation using maneuvers such as funic decompression and bladder filling can reduce pressure on the cord while preparations are being made for delivery. (See",
"      <a class=\"local\" href=\"#H1942694\">",
"       'Intrauterine resuscitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Good neonatal outcomes have been reported in the majority of patients with cord prolapse. The interval between cord prolapse and delivery is a major determining factor in the immediate neonatal outcome and perinatal mortality, but not the only factor. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not suggest routine sonography in all patients to assess umbilical cord position. Ultrasound examination should be used to confirm cord position when there is a clinical suspicion of funic presentation. Pregnancies with persistent funic presentation can be delivered by cesarean, however, there are no properly controlled trials to provide a recommended mode of delivery in this setting. (See",
"      <a class=\"local\" href=\"#H496167\">",
"       'Pregnancies with funic presentation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/1\">",
"      Koonings PP, Paul RH, Campbell K. Umbilical cord prolapse. A contemporary look. J Reprod Med 1990; 35:690.",
"     </a>",
"    </li>",
"    <li>",
"     Barclay, M. Umbilical cord prolapse and other cord accidents. In: Gynecology and Obstetrics, Sciarra, JJ (ed), JB Lippincott, Philadelphia, PA 1989. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/3\">",
"      Yl&auml;-Outinen A, Heinonen PK, Tuimala R. Predisposing and risk factors of umbilical cord prolapse. Acta Obstet Gynecol Scand 1985; 64:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/4\">",
"      Uygur D, Ki�� S, Tuncer R, et al. Risk factors and infant outcomes associated with umbilical cord prolapse. Int J Gynaecol Obstet 2002; 78:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/5\">",
"      Murphy DJ, MacKenzie IZ. The mortality and morbidity associated with umbilical cord prolapse. Br J Obstet Gynaecol 1995; 102:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/6\">",
"      Critchlow CW, Leet TL, Benedetti TJ, Daling JR. Risk factors and infant outcomes associated with umbilical cord prolapse: a population-based case-control study among births in Washington State. Am J Obstet Gynecol 1994; 170:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/7\">",
"      Qureshi NS, Taylor DJ, Tomlinson AJ. Umbilical cord prolapse. Int J Gynaecol Obstet 2004; 86:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/8\">",
"      Altaras M, Potashnik G, Ben-Adereth N, Leventhal H. The use of vacuum extraction in cases of cord prolapse during labor. Am J Obstet Gynecol 1974; 118:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/9\">",
"      Kahana B, Sheiner E, Levy A, et al. Umbilical cord prolapse and perinatal outcomes. Int J Gynaecol Obstet 2004; 84:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/10\">",
"      Roberts WE, Martin RW, Roach HH, et al. Are obstetric interventions such as cervical ripening, induction of labor, amnioinfusion, or amniotomy associated with umbilical cord prolapse? Am J Obstet Gynecol 1997; 176:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/11\">",
"      Berghella V. Prolapsed cord after external cephalic version in a patient with premature rupture of membranes and transverse lie. Eur J Obstet Gynecol Reprod Biol 2001; 99:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/12\">",
"      Boyle JJ, Katz VL. Umbilical cord prolapse in current obstetric practice. J Reprod Med 2005; 50:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/13\">",
"      Usta IM, Mercer BM, Sibai BM. Current obstetrical practice and umbilical cord prolapse. Am J Perinatol 1999; 16:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/14\">",
"      Gannard-Pechin E, Ramanah R, Cossa S, et al. [Umbilical cord prolapse: a case study over 23 years]. J Gynecol Obstet Biol Reprod (Paris) 2012; 41:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/15\">",
"      Katz Z, Shoham Z, Lancet M, et al. Management of labor with umbilical cord prolapse: a 5-year study. Obstet Gynecol 1988; 72:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/16\">",
"      Barrett JM. Funic reduction for the management of umbilical cord prolapse. Am J Obstet Gynecol 1991; 165:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/17\">",
"      Prabulos AM, Philipson EH. Umbilical cord prolapse. Is the time from diagnosis to delivery critical? J Reprod Med 1998; 43:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/18\">",
"      Panter KR, Hannah ME. Umbilical cord prolapse: so far so good? Lancet 1996; 347:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/19\">",
"      Siassakos D, Hasafa Z, Sibanda T, et al. Retrospective cohort study of diagnosis-delivery interval with umbilical cord prolapse: the effect of team training. BJOG 2009; 116:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/20\">",
"      Nizard J, Cromi A, Molendijk H, Arabin B. Neonatal outcome following prolonged umbilical cord prolapse in preterm premature rupture of membranes. BJOG 2005; 112:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/21\">",
"      Poetker DM, Rijhsinghani A. Fetal survival after umbilical cord prolapse for more than three days. A case report. J Reprod Med 2001; 46:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/22\">",
"      Gilbert WM, Jacoby BN, Xing G, et al. Adverse obstetric events are associated with significant risk of cerebral palsy. Am J Obstet Gynecol 2010; 203:328.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/23\">",
"      Lange IR, Manning FA, Morrison I, et al. Cord prolapse: is antenatal diagnosis possible? Am J Obstet Gynecol 1985; 151:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/24\">",
"      Raga F, Osborne N, Ballester MJ, Bonilla-Musoles F. Color flow Doppler: a useful instrument in the diagnosis of funic presentation. J Natl Med Assoc 1996; 88:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/25\">",
"      Kinugasa M, Sato T, Tamura M, et al. Antepartum detection of cord presentation by transvaginal ultrasonography for term breech presentation: potential prediction and prevention of cord prolapse. J Obstet Gynaecol Res 2007; 33:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29494/abstract/26\">",
"      Ezra Y, Strasberg SR, Farine D. Does cord presentation on ultrasound predict cord prolapse? Gynecol Obstet Invest 2003; 56:6.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4461 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-04D01F2D42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_51_29494=[""].join("\n");
var outline_f28_51_29494=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS AND ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fetomaternal factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Iatrogenic obstetrical intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1942694\">",
"      Intrauterine resuscitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Funic decompression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1942733\">",
"      - Bladder filling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Funic reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H496167\">",
"      Pregnancies with funic presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4461\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4461|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/45/20181\" title=\"diagnostic image 1A\">",
"      Doppler umbilical cord prolapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/2/34853\" title=\"diagnostic image 1B\">",
"      Doppler cord prolapse2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/54/23397\" title=\"diagnostic image 1C\">",
"      Doppler cord prolapse3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4461|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/16/9483\" title=\"table 1\">",
"      Risk factors for cord prolapse",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40840?source=related_link\">",
"      Gross examination of the placenta",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_51_29495="Estradiol and norgestimate: Drug information";
var content_f28_51_29495=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Estradiol and norgestimate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/54/5990?source=see_link\">",
"    see \"Estradiol and norgestimate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F167248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Prefest&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F167263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Estrogen and Progestin Combination",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F167251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Females with an intact uterus:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of menopausal symptoms, atrophic vaginitis, prevention of osteoporosis:",
"     </b>",
"     Oral: Treatment is cyclical and consists of the following: One tablet of estradiol 1 mg (pink tablet) once daily for 3 days, followed by 1 tablet of estradiol 1 mg and norgestimate 0.09 mg (white tablet) once daily for 3 days; repeat sequence continuously.",
"     <b>",
"      Note:",
"     </b>",
"     This dose may not be the lowest effective combination for these indications. In case of a missed tablet, restart therapy with next available tablet in sequence (taking only 1 tablet each day).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F167252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15837945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15837946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F167227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prefest&trade;: Estradiol 1 mg [15 peach tablets] and estradiol 1 mg and norgestimate 0.09 mg [15 white tablets]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F167212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F167229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In case of a missed tablet, restart therapy with next available tablet in sequence (taking only 1 tablet each day). Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F167228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Women with an intact uterus: Treatment of moderate-to-severe vasomotor symptoms associated with menopause; treatment of atrophic vaginitis; prevention of osteoporosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14853862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high [oral and transdermal patch]; Strength of recommendation - strong [oral and transdermal patch]).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F167261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (6%), pain (6%), depression (5%), dizziness (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Vaginal bleeding (9%), dysmenorrhea (8%), vaginitis (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (6%), flatulence (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (9%), myalgia (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sinusitis (8%), pharyngitis (7%), cough (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Viral infection (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Additional adverse effects associated with",
"     <b>",
"      estrogens and progestins",
"     </b>",
"     ; frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema, hypertension, MI, stroke, venous thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety, epilepsy exacerbation, insomnia, irritability, migraine, mood disturbances, nervousness, pyrexia, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne, chloasma, erythema multiforme, erythema nodosum, hemorrhagic eruptions, hirsutism, itching, melasma, pruritus, rash, scalp hair loss, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, breast cancer, breast discharge, breast enlargement, Breast tenderness, carbohydrate tolerance decreased, endometrial cancer, endometrial hyperplasia, fibrocystic breast changes, galactorrhea, hypocalcemia, libido changes, ovarian cancer, triglycerides increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, appetite changes, bloating, gallbladder disease, pancreatitis, vomiting, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Abnormal withdrawal bleeding/flow, breakthrough bleeding, cervical secretion changes, cystitis syndrome, uterine leiomyomata size increased, vaginal candidiasis, vaginal bleeding/spotting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia, porphyria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Chorea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Contact lens intolerance, corneal curvature steepening, neuro-ocular lesions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Asthma exacerbation, pulmonary embolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F167232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to estradiol, norgestimate, or any component of the formulation; undiagnosed abnormal vaginal bleeding; history of or current thrombophlebitis or venous thromboembolic disorders (including DVT, PE); active or recent (within 1 year) arterial thromboembolic disease (eg, stroke, MI); carcinoma of the breast; estrogen-dependent tumor; hepatic dysfunction or disease;  pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F167216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer:",
"     <b>",
"      [U.S. Boxed Warning]: Based on data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in postmenopausal women using conjugated estrogens (CE) in combination with medroxyprogesterone acetate (MPA).",
"     </b>",
"     This risk may be associated with duration of use and declines once combined therapy is discontinued (Chlebowski, 2009). The risk of invasive breast cancer was decreased in postmenopausal women with a hysterectomy using CE only, regardless of weight. However, the risk was not significantly decreased in women at high risk for breast cancer (family history of breast cancer, personal history of benign breast disease) (Anderson, 2012). An increase in abnormal mammogram findings has also been reported with estrogen alone or in combination with progestin therapy. Estrogen use may also lead to severe hypercalcemia in patients with breast cancer and bone metastases; discontinue estrogen if hypercalcemia occurs. Use is contraindicated in patients with known or suspected breast cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent dementia. In the Women&rsquo;s Health Initiative Memory Study (WHIMS), an increased incidence of dementia was observed in women &ge;65 years of age taking CE alone or in combination with MPA.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endometrial carcinoma: The use of unopposed estrogen in women with an intact uterus is associated with an increased risk of endometrial cancer. The addition of a progestin to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Adequate diagnostic measures, including endometrial sampling if indicated, should be performed to rule out malignancy in postmenopausal women with undiagnosed abnormal vaginal bleeding. Estrogens may exacerbate endometriosis. Malignant transformation of residual endometrial implants has been reported posthysterectomy with unopposed estrogen therapy. Consider adding a progestin in women with residual endometriosis posthysterectomy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inherited thrombophilia: Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho, 2010; van Vlijmen, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased; use with caution in patients with familial defects of lipoprotein metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian cancer: Postmenopausal estrogen therapy and combined estrogen/progesterone therapy may increase the risk of ovarian cancer; however, the absolute risk to an individual woman is small. Although results from various studies are not consistent, risk does not appear to be significantly associated with the duration, route, or dose of therapy. In one study, the risk decreased after 2 years following discontinuation of therapy (M&oslash;rch, 2009). Although the risk of ovarian cancer is rare, women who are at an increased risk (eg, family history) should be counseled about the association (NAMS, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia, or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use caution in patients with asthma; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent cardiovascular disease.",
"     </b>",
"     Using data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of deep vein thrombosis (DVT) and stroke has been reported with CE and an increased risk of DVT, stroke, pulmonary emboli (PE) and myocardial infarction (MI) has been reported with CE with MPA in postmenopausal women. Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of venous thromboembolism (VTE). Risk factors should be managed appropriately; discontinue use if adverse cardiovascular events occur or are suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including cardiac or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Epilepsy: Use caution with epilepsy; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: Use of postmenopausal estrogen may be associated with an increased risk of gallbladder disease requiring surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic dysfunction: Estrogens are poorly metabolized in patients with hepatic dysfunction. Use caution with a history of cholestatic jaundice associated with prior estrogen use or pregnancy. Discontinue if jaundice develops or if acute or chronic hepatic disturbances occur. Use is contraindicated with hepatic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic hemangiomas: Use with caution in patients with hepatic hemangiomas; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hereditary angioedema: Exogenous estrogens may exacerbate angioedema symptoms in women with hereditary angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypocalcemia: Use with caution in patients with severe hypocalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Migraine: Use caution with migraine; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use with caution in patients with porphyria; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SLE: Use with caution in patients with SLE; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid oral and transdermal patch estrogen products (with or without progestins) in this age group due to potential of increased risk of breast and endometrial cancers, and lack of proven cardioprotection and cognitive protection (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Premenopausal women: Not for use prior to menopause.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, should be discontinued at least 4-6 weeks prior to elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis use: For use only in women at significant risk of osteoporosis and for who other nonestrogen medications are not considered appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Risks vs benefits:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should be used for the shortest duration possible at the lowest effective dose consistent with treatment goals.",
"     </b>",
"     Before prescribing estrogen therapy to postmenopausal women, the risks and benefits must be weighed for each patient. Women should be informed of these risks and benefits, as well as possible effects of progestin when added to estrogen therapy. Patients should be reevaluated as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from Women&rsquo;s Health Initiative (WHI) studies, which evaluated oral CE 0.625 mg with or without MPA 2.5 mg relative to placebo in postmenopausal women. Other combinations and dosage forms of estrogens and progestins were not studied.",
"     <b>",
"      Outcomes reported from clinical trials using CE with or without MPA should be assumed to be similar for other doses and other dosage forms of estrogens and progestins until comparable data becomes available.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vulvar and vaginal atrophy use: When used solely for the treatment of vulvar and vaginal atrophy, topical vaginal products should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F167259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F167220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women.  Management: Monitor for reduced growth hormone efficacy. A larger somatropin dose may be required to reach treatment goal.  This interaction does not appear to apply to non-orally administered estrogens (e.g., transdermal, vaginal ring).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F167243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (routine use increases estrogen level and risk of breast cancer). Ethanol may also increase the risk of osteoporosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: CNS effects of caffeine may be enhanced if combination estrogen/progestins are used concurrently with caffeine. Grapefruit juice increases ethinyl estradiol concentrations and would be expected to increase progesterone serum levels as well; clinical implications are unclear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease the plasma levels of combination estrogen/progestin combinations by inducing hepatic enzymes. Avoid dong quai and black cohosh (have estrogen activity). Avoid saw palmetto, red clover, ginseng.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F167223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F167235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Estrogens are not indicated for use during pregnancy or immediately postpartum. Increased risk of fetal reproductive tract disorders and other birth defects have been observed with diethylstilbestrol (DES); do not use during pregnancy. Progestins are associated with fetal genital abnormalities when used during the first trimester; not recommended for use during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F167255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F167236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Estrogens and progestins are excreted in breast milk. Estrogens decrease the quality and quantity of breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F167237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ensure adequate calcium and vitamin D intake when used for the prevention of osteoporosis.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F167234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Prefest Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1/1-0.09 mg (30): $109.10",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F167225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yearly physical examination that includes blood pressure and Papanicolaou smear, breast exam, mammogram. Monitor for signs of endometrial cancer. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding. Monitor for loss of vision, sudden onset of proptosis, diplopia, migraine; signs and symptoms of thromboembolic disorders; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias; thyroid function in patients on thyroid hormone replacement therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Menopausal symptoms: Assess need for therapy at 3- to 6-month intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevention of osteoporosis: Bone density measurement",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F167215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Estrogens are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estradiol is the principle intracellular human estrogen and is more potent than estrone and estriol at the receptor level; it is the primary estrogen secreted prior to menopause. Following menopause, estrone and estrone sulfate are more highly produced. Estrogens modulate the pituitary secretion of gonadotropins, luteinizing hormone, and follicle-stimulating hormone through a negative feedback system; estrogen replacement reduces elevated levels of these hormones in postmenopausal women.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Progestins inhibit gonadotropin production which then prevents follicular maturation and ovulation. In women with adequate estrogen, progestins transform a proliferative endometrium into a secretory endometrium; when administered with estradiol, reduces the incidence of endometrial hyperplasia and risk of adenocarcinoma.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F167231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Estradiol:",
"     </b>",
"     See Estradiol (Systemic) monograph.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Norgestimate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Protein binding: 17-deacetylnorgestimate: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolism: Forms 17-deacetylnorgestimate (major active metabolite) and other metabolites; first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Half-life elimination: 17-deacetylnorgestimate: 37 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Excretion: Norgestimate metabolites: Urine and feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/51/29495/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Chlebowski RT, Aragaki AK, et al, \"Conjugated Equine Oestrogen and Breast Cancer Incidence and Mortality in Postmenopausal Women With Hysterectomy: Extended Follow-Up of the Women's Health Initiative Randomised Placebo-Controlled Trial,\"",
"      <i>",
"       Lancet Oncol,",
"      </i>",
"      2012,13(5):476-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/51/29495/abstract-text/22401913/pubmed\" id=\"22401913\" target=\"_blank\">",
"        22401913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Limacher M, Assaf AR, et al, \"Effects of Conjugated Equine Estrogen In Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial.\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 291(14):1701-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/51/29495/abstract-text/15082697/pubmed\" id=\"15082697\" target=\"_blank\">",
"        15082697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chlebowski RT, Kuller LH, Prentice RL, et al, \"Breast Cancer After Use of Estrogen Plus Progestin in Postmenopausal Women,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(6):573-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/51/29495/abstract-text/19196674/pubmed\" id=\"19196674\" target=\"_blank\">",
"        19196674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSancho MT, Dorff T, and Rand JH, \"Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,\"",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 2010, 21(6):534-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/51/29495/abstract-text/20581664/pubmed\" id=\"20581664\" target=\"_blank\">",
"        20581664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hsia J, Langer RD, Manson JE, et al, \"Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2006, 166(3):357-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/51/29495/abstract-text/16476878/pubmed\" id=\"16476878\" target=\"_blank\">",
"        16476878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      M&oslash;rch LS, L&oslash;kkegaard E, Andreasen AH, et al, &ldquo;Hormone Therapy and Ovarian Cancer,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2009, 302(3):298-305.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/51/29495/abstract-text/19602689/pubmed\" id=\"19602689\" target=\"_blank\">",
"        19602689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      North American Menopause Society [NAMS], \"The 2012 Hormone Therapy Position Statement of The North American Menopause Society,\"",
"      <i>",
"       Menopause",
"      </i>",
"      , 2012, 19(3):257-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/51/29495/abstract-text/22367731/pubmed\" id=\"22367731\" target=\"_blank\">",
"        22367731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al, &ldquo;Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principle Results From the Women's Health Initiative Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(3):321-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/51/29495/abstract-text/12117397/pubmed\" id=\"12117397\" target=\"_blank\">",
"        12117397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shumaker SA, Legault C, Rapp SR, et al, &ldquo;Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(20):2651-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/51/29495/abstract-text/12771112/pubmed\" id=\"12771112\" target=\"_blank\">",
"        12771112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Food and Drug Administration, Department of Health and Human Services, &ldquo;WHIMS Study on Estrogen/Progestin,&rdquo; May 27, 2003. Available at",
"      <a href=\"file://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm\" target=\"_blank\">",
"       file://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al, \"Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(8):2055-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/51/29495/abstract-text/21659542/pubmed\" id=\"21659542\" target=\"_blank\">",
"        21659542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8669 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-4554544F47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_51_29495=[""].join("\n");
var outline_f28_51_29495=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708752\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167248\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167263\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167251\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167252\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15837945\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15837946\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167227\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167212\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167229\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167228\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14853862\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167261\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167232\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167216\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167259\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167220\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167243\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167223\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167235\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167255\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167236\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167237\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167234\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167225\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167215\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167231\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8669\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8669|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/54/5990?source=related_link\">",
"      Estradiol and norgestimate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_51_29496="Complete airway obstruction in children";
var content_f28_51_29496=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55990%7EEM%2F54996%7EEM%2F58510%7EEM%2F73112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55990%7EEM%2F54996%7EEM%2F58510%7EEM%2F73112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 571px\">",
"   <div class=\"ttl\">",
"    Management of complete airway obstruction in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 551px; height: 700px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ORL: otorhinolaryngologist (ear-nose-throat specialist); OR: operating room; BLS: basic life support; LMA: laryngeal mask airway; ICU: intensive care unit; ETT: endotracheal tube.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Management of severe upper airway obstruction in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 761px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ORL: otolaryngologist; OR: operating room.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The difficult airway algorithm&copy;",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 361px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BMV: bag-mask ventilation; EGD: extra-glottic device; DL: direct laryngoscopy; FO: fiberoptic method; VL: video laryngoscopy; RSI: rapid sequence intubation; ILMA: intubating laryngeal mask; BNTI: blind nasotracheal intubation.",
"     <br/>",
"     * RSI may require a double set-up. See text for details.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     If not used for awake laryngoscopy.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Difficult Airway Course&reg;: Emergency and Walls RM, Murphy MF. Manual of Emergency Airway Management,&nbsp;4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The failed airway algorithm&copy;",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 393px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * In children under 8 years of age an uncuffed or cuffed endotracheal tube may be placed. In neonates, uncuffed endotracheal tubes should be placed.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Difficult Airway Course&reg;: Emergency and Walls RM, Murphy MF. Manual of Emergency Airway Management, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_51_29496=[""].join("\n");
var outline_f28_51_29496=null;
var title_f28_51_29497="Superficial spreading melanoma";
var content_f28_51_29497=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57466%7EPC%2F78826%7EPC%2F80955%7EPC%2F62105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57466%7EPC%2F78826%7EPC%2F80955%7EPC%2F62105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superficial spreading melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 206px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Asymmetry and color variegation are characteristic of superficial spreading melanomas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James C Shaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acral lentiginous melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 193px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An acral lentiginous melanoma shows the asymmetry and color variegation of typical melanomas. They are distinguished clinically by their location on the palms, soles, or nails.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James C Shaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 193px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nodular melanomas present a discrete nodule, usually with dark pigmentation, although they may be amelanotic, as depicted above.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James C Shaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lentigo maligna melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 423px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lentigo maligna melanoma usually arises in areas of sun-damaged skin, particularly on the head and neck. It begins as a freckle-like, tan-brown macule and gradually enlarges and develops darker or lighter asymmetric foci and raised areas, which signify dermal invasion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Susan Swetter, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_51_29497=[""].join("\n");
var outline_f28_51_29497=null;
var title_f28_51_29498="Treatment of relapsed or refractory acute myeloid leukemia";
var content_f28_51_29498=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of relapsed or refractory acute myeloid leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/51/29498/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/51/29498/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/51/29498/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/51/29498/contributors\">",
"     Bob Lowenberg, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/51/29498/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/51/29498/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/51/29498/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the successful treatment of a patient with acute myeloid leukemia (AML) is the attainment of a complete remission (CR), which is characterized by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal values for absolute neutrophil count",
"      <span class=\"nowrap\">",
"       (&gt;1000/microL)",
"      </span>",
"      and platelet count",
"      <span class=\"nowrap\">",
"       (&gt;100,000/microL),",
"      </span>",
"      and independence from red cell transfusion.",
"     </li>",
"     <li>",
"      A bone marrow biopsy that reveals no clusters or collections of blast cells. Extramedullary leukemia (eg, central nervous system or soft tissue involvement) must be absent.",
"     </li>",
"     <li>",
"      A bone marrow aspiration revealing normal maturation of all cellular components (ie, erythroid, granulocytic, and megakaryocytic series). There is no requirement for bone marrow cellularity.",
"     </li>",
"     <li>",
"      Less than 5 percent of blast cells present in the bone marrow, and none with a leukemic phenotype (eg, Auer rods). The persistence of dysplasia is worrisome as an indicator of residual AML, but has not been validated as a criterion for remission status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Twenty to 30 percent of young adult patients and 50 percent of older adult patients with newly diagnosed AML will fail to attain a CR with intensive induction chemotherapy due to drug resistance or death. In addition, a percentage of patients who initially attain a CR will relapse. Treatment of the patient with AML who has failed to enter into CR or who has relapsed after attainment of CR will be reviewed here. The prognosis and initial treatment of the patient with AML are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=see_link\">",
"     \"Treatment of acute myeloid leukemia in older adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36730?source=see_link\">",
"     \"Prognosis of acute myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=see_link\">",
"     \"Remission criteria in acute myeloid leukemia and monitoring for residual disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H625274\">",
"    <span class=\"h1\">",
"     EVALUATION FOR RELAPSE OR RESISTANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261038589\">",
"    <span class=\"h2\">",
"     Definitions of relapse and refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refractory (resistant) disease is defined by the failure to obtain a complete remission (CR) with induction therapy. This is also referred to as primary induction failure. In such cases, induction chemotherapy has failed to eradicate all detectable leukemia cells (less than 5 percent blasts) from the bone marrow and blood with subsequent restoration of normal hematopoiesis (greater than 25 percent marrow cellularity and normal peripheral blood counts). Patients who require two cycles of induction therapy to attain a first CR are not considered to have refractory disease. Depending upon post-remission therapy, they appear to have a similar prognosis to those who attain a CR with initial induction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/1\">",
"     1",
"    </a>",
"    ]. Resistance to induction chemotherapy is closely associated with unfavorable cytogenetic features and poor overall outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=see_link\">",
"     \"Remission criteria in acute myeloid leukemia and monitoring for residual disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After attaining a CR with initial therapy, patients are followed at routine intervals to monitor for treatment-related complications and relapse. Relapsed disease describes the reappearance of leukemia cells in the bone marrow or peripheral blood or elsewhere in the body (other",
"    <span class=\"nowrap\">",
"     tissues/organs)",
"    </span>",
"    after the attainment of a CR. As yet, the significance of the reappearance of AML detected only by polymerase chain reaction (PCR) analysis is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17274?source=see_link&amp;anchor=H19#H19\">",
"     \"Post-remission therapy for acute myeloid leukemia in younger adults\", section on 'Monitoring for relapse'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=see_link&amp;anchor=H14#H14\">",
"     \"Remission criteria in acute myeloid leukemia and monitoring for residual disease\", section on 'Use in non-APL AML'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21582911\">",
"    <span class=\"h2\">",
"     Evaluation of suspected relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients suspected of having relapsed disease should be evaluated with a unilateral bone marrow aspiration. The use of a trephine biopsy for all patients is controversial. A trephine biopsy is required if the marrow is inaspirable and may add useful diagnostic information above that obtained from a bone marrow aspiration alone in other patients. This sample should be sent for pathologic review, immunophenotyping, cytochemistry, and cytogenetics. Mutation analysis for c-KIT, CEBPA, FLT3-ITD, and NPM1 mutations should be performed, if readily available, even if performed at the time of initial diagnosis since they might change at the time of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once relapsed or refractory disease is identified, further evaluation should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An assessment of performance status (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Human leukocyte antigen (HLA) typing should be performed for patients who are candidates for hematopoietic cell transplantation (HCT). If no sibling donor can be identified, an alternative donor search (including cord blood) should be initiated. This is extremely important since HCT is the most likely method for curing patients with relapsed AML. (See",
"      <a class=\"local\" href=\"#H70422874\">",
"       'Determining transplant eligibility'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Other laboratory studies include a complete blood count with differential, chemistries with liver and renal function and electrolytes, glucose, lactate dehydrogenase (LDH), calcium, phosphorus, uric acid, albumin and total protein, serum lysozyme, and serology for hepatitis B, HIV, herpes simplex virus (HSV) and cytomegalovirus (CMV) infection. An elevation in serum or urinary lysozyme levels may explain renal dysfunction in monocytic and myelomonocytic leukemia. Women of childbearing age should undergo a pregnancy test.",
"     </li>",
"     <li>",
"      A chest x-ray, pulmonary function tests, an electrocardiogram (EKG) and a study of cardiac function (eg, ejection fraction measured by echocardiogram or MUGA) should be performed.",
"     </li>",
"     <li>",
"      Dental evaluation with x-rays for possible infection foci is warranted. CT scans of the sinuses and chest may detect clinically occult sites of infection, although the yield in asymptomatic patients is unknown.",
"     </li>",
"     <li>",
"      Patients with neurologic signs or symptoms should undergo imaging studies to evaluate for meningeal disease, or central nervous system bleeding. Lumbar puncture is indicated in patients with neurologic signs or symptoms to examine the cerebrospinal fluid (CSF) for leukemic involvement. Care must be taken to avoid contaminating the CSF specimen with peripheral blood if blasts were present. CSF should be sent for both cytology (examination of stained cytospin slides) and flow cytometry for detection of AML blasts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261041554\">",
"    <span class=\"h1\">",
"     SELECTION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapy that provides the best chance to cure a patient with relapsed or refractory AML is an allogeneic hematopoietic cell transplantation (HCT). The best outcomes appear to be with myeloablative preparative regimens administered after attaining a complete remission (CR). However, some patients may be cured with myeloablative HCT despite residual disease at the time of HCT. In addition, nonmyeloablative preparative regimens may be considered for patients who are not candidates for myeloablative HCT, but have attained a CR. Autologous marrow transplantation is an option for those patients who achieve a second CR. A physician who specializes in transplantation should be consulted at the time relapsed or refractory disease is identified to help guide this decision process.",
"   </p>",
"   <p>",
"    The decision of whether to attempt a second remission induction prior to HCT depends upon several factors, such as age, comorbidities, duration of first remission, cytogenetic features, access to an experienced transplant center, resources for home care, and of course, the patient&rsquo;s own wishes. Important questions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      How likely is the patient to attain a CR? Patients who undergo HCT in CR appear to have better outcomes. Patients who previously attained a CR that lasted longer than six months have a greater than 50 percent chance of attaining a second CR with further chemotherapy. In contrast, of patients with initially refractory disease and those with an initial CR lasting less than six months, 20 percent or fewer will attain a second CR with chemotherapy alone. (See",
"      <a class=\"local\" href=\"#H21583133\">",
"       'Prognostic indices'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Is an HLA-matched donor immediately available? If a matched donor is not available for immediate collection, chemotherapy administered in the attempt to achieve a CR may control the disease while a search for a compatible donor is undertaken. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"       \"Donor selection for hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Is the patient a candidate for a myeloablative preparative regimen? Myeloablative HCT eradicates tumor cells through both a direct cytotoxic effect and a graft-versus-leukemia (GVL) effect. In contrast, nonmyeloablative preparative regimens rely in large part upon an immunological GVL effect alone. Nonmyeloablative HCT is not appropriate for patients with refractory or rapidly progressive AML. (See",
"      <a class=\"local\" href=\"#H70422035\">",
"       'Nonmyeloablative (reduced intensity) HCT'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      How did the patient tolerate induction therapy before? Attempts at a second induction may result in toxicity that limits the ability to proceed with a potentially curative HCT.",
"     </li>",
"     <li>",
"      Does the patient have active infections (ie, aspergillosis) that are associated with a high mortality rate at HCT? (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19974?source=see_link\">",
"       \"Evaluation for infection before hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There have been no randomized trials of HCT with or without chemotherapy administered in an attempt at inducing a second remission. As such, clinical practice varies. Some experts choose to administer or not administer further induction chemotherapy prior to myeloablative HCT based upon the likelihood of achieving a second CR [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/3\">",
"     3",
"    </a>",
"    ]. With this approach, a young patient who had an initial prolonged CR may be given further chemotherapy prior to HCT because more than half of such patients would be expected to attain a second CR. In contrast, further chemotherapy may be deferred for a patient with an initial CR lasting less than six months since it may only prove to worsen the functional status and decrease the chance of a successful HCT. Instead, it may be reasonable to proceed to HCT without prior chemotherapy if the patient is a good candidate for a myeloablative HCT and a donor is available. If the patient is not a candidate for a myeloablative HCT, then a CR should be attained prior to nonmyeloablative HCT. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Myeloablative HCT'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A pretransplant scoring system has been devised to predict the survival of patients not in CR who undergo myeloablative HCT based upon the assessment of five criteria (maximum score 6 points) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Duration of CR: First CR &le;6 months = 1 point",
"     </li>",
"     <li>",
"      Cytogenetics prior to HCT: Poor risk = 1 point",
"     </li>",
"     <li>",
"      Donor: Mismatched unrelated donor = 1 point; Related donor other than HLA identical sibling = 2 points",
"     </li>",
"     <li>",
"      Circulating blasts: present = 1 point",
"     </li>",
"     <li>",
"      Karnofsky performance status: &lt;90 = 1 point",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Total score predicted long-term survival when applied to 1673 patients with relapsed or refractory AML not in CR at the time of myeloablative HCT. Rates of three-year overall survival were 42, 28, 15, and 6 percent for patients with 0, 1, 2, and 3 points, respectively. Given these data, some clinicians may choose to proceed with myeloablative HCT without further induction chemotherapy if the patient has a score &le;2 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/4\">",
"     4",
"    </a>",
"    ]. For patients with a score of &ge;3, myeloablative HCT is unlikely to be of benefit; further induction chemotherapy may be administered to these patients in an attempt to decrease the tumor burden and improve the performance status prior to reconsideration of HCT. Alternatively, such patients may be considered for a clinical trial of an investigational agent. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Experimental agents or protocols'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, not all patients will require further induction chemotherapy prior to myeloablative hematopoietic cell transplantation (HCT) while all patients undergoing a nonmyeloablative HCT should undergo further induction chemotherapy in order to attain a complete remission (CR) prior to HCT. Consultation with a physician who specializes in HCT can help with the decision process. If further induction chemotherapy is warranted, the goal of therapy is to attain a CR prior to proceeding with allogeneic HCT. Patients who are not candidates for a myeloablative HCT whose relapsed AML demonstrates a highly unfavorable genotype (eg, monosomal karyotype) are unlikely to respond to standard chemotherapy regimens and should be considered for investigational agents. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Experimental agents or protocols'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A number of chemotherapy regimens have been used for patients with resistant or relapsed disease. Many of these combinations are dose-intensive and cannot easily be applied in older patients. Since these regimens have not been directly compared, a choice is primarily based upon clinical experience. Although response rates are presented for some of these regimens, an individual&rsquo;s chance of responding to a particular regimen is influenced not only by prior exposure to chemotherapy but also by other patient- and leukemia-associated factors. In theory, the preferred regimen would exclude agents at dose levels for salvage which the patient has been exposed to recently. (See",
"    <a class=\"local\" href=\"#H21583133\">",
"     'Prognostic indices'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The most commonly used regimens are (",
"    <a class=\"graphic graphic_table graphicRef82823 \" href=\"UTD.htm?31/19/32061\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Re-induction with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      will produce CR in approximately 50 percent of patients with a first remission greater than one year [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link&amp;anchor=H6#H6\">",
"       \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Standard dose cytarabine plus an anthracycline (7+3)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      (HDAC) regimen using 2 to 3",
"      <span class=\"nowrap\">",
"       g/m2",
"      </span>",
"      every 12 hours for 8 to 12 doses may be effective in 35 to 40 percent of patients resistant to conventional dose cytarabine regimens [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/7\">",
"       7",
"      </a>",
"      ]. If an anthracycline (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      ) was not used during initial induction, the combination of HDAC plus an anthracycline may produce higher response rates than HDAC alone [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/8\">",
"       8",
"      </a>",
"      ]. Side effects appear to be similar with the two regimens. The most common nonhematologic toxicities are",
"      <span class=\"nowrap\">",
"       nausea/vomiting,",
"      </span>",
"      abnormal liver chemistries, diarrhea, conjunctivitis, rash, and cerebellar dysfunction. Toxicity is prohibitively high in most patients over the age of 60 years. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link&amp;anchor=H11#H11\">",
"       \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'High dose cytarabine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       Mitoxantrone",
"      </a>",
"      (10 to 12",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per day) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per day) given together for five days is a commonly used regimen to treat refractory or relapsed AML and has demonstrated CR rates of approximately 40 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/3,9-11\">",
"       3,9-11",
"      </a>",
"      ]. Nonhematologic toxicities include stomatitis, nausea, infections, and neutropenic fever. Infrequent transient, mild cardiac failure and tachyarrhythmias have also been reported.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       Mitoxantrone",
"      </a>",
"      has also been used in various combinations with high and intermediate-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      (the HAM regimen), both with and without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]. In one series of 47 patients with recurrent or refractory AML, the combination of mitoxantrone (5",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per day for 5 days) and intermediate-dose cytarabine (0.5",
"      <span class=\"nowrap\">",
"       g/m2",
"      </span>",
"      IV every 12 hours for 6 days) resulted in a complete remission rate of 62 percent, but the median duration of remission was only 3.7 months [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/15\">",
"       15",
"      </a>",
"      ]. Ninety-six percent of those achieving CR eventually relapsed. Three patients &ge;60 developed acute cerebellar toxicity.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       Fludarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      , plus G-CSF (FLAG) has reported complete remission rates of 45 to 55 percent in patients with primary refractory or relapsing AML [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. Studies including older adults have reported mild nonhematologic toxicity most commonly included mucositis. Median survival was &gt;16 months for those with late relapse (ie, &gt;6 months after stopping chemotherapy), but was only three months for those with early relapse or refractory disease [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"       cladribine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      plus G-CSF has been administered with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"       idarubicin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. Complete remissions were seen in 40 to 50 percent of patients. Common nonhematopoietic toxicities were infection and bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other regimens that have demonstrated efficacy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       Etoposide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       Cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      (ADE), given together or sequentially [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/53/9046?source=see_link\">",
"       Liposomal daunorubicin",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Gemtuzumab, intermediate-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      (MIDAM) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/24\">",
"       24",
"      </a>",
"      ]. Gemtuzumab has been removed from the market in the United States. (See",
"      <a class=\"local\" href=\"#H21585075\">",
"       'Gemtuzumab'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/5/33879?source=see_link\">",
"       Clofarabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      with or without G-CSF (CLAG) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chemotherapy for relapsed or refractory AML is highly toxic, primarily to the hematopoietic system, and most patients will have a prolonged hospital stay and will require blood product support. Supportive care of cytopenias, infections, and other complications in the setting of AML is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link&amp;anchor=H14#H14\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Supportive care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21584407\">",
"    <span class=\"h1\">",
"     HEMATOPOIETIC CELL TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic hematopoietic cell transplantation (HCT) is the therapy with the greatest chance of attaining a cure for a patient with relapsed or refractory AML. However, autologous HCT may also yield a durable remission after relapse in approximately 15 to 20 percent of patients who attain a second complete remission with chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/27\">",
"     27",
"    </a>",
"    ]. &nbsp;Some patients should be given induction chemotherapy prior to allogeneic HCT in an effort to achieve a complete remission. Others may proceed directly to HCT. A physician who specializes in HCT should be consulted at the time relapsed or refractory disease is identified to help guide this decision process. (See",
"    <a class=\"local\" href=\"#H261041554\">",
"     'Selection of therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70422874\">",
"    <span class=\"h2\">",
"     Determining transplant eligibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eligibility for allogeneic HCT varies across countries and institutions. The mortality associated with allogeneic HCT has declined likely related to reductions in organ damage, infection, and severe acute graft-versus-host disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. An age cutoff of 55 years is commonly used for myeloablative HCT. However, age alone should not be a determining factor of transplant eligibility. Instead, decisions are made on a case-by-case basis (based upon \"physiologic age\") and vary across institutions.",
"   </p>",
"   <p>",
"    In most centers in the United States, patients with one or more of the following factors are not considered eligible for myeloablative HCT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary function DLCO, FVC &lt;60 percent",
"     </li>",
"     <li>",
"      Direct bilirubin &gt;2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      SGOT or SGPT &gt;2x upper limit of normal",
"     </li>",
"     <li>",
"      Serum creatinine &gt;1.5",
"      <span class=\"nowrap\">",
"       mg/dL;",
"      </span>",
"      creatinine clearance &lt;60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"     </li>",
"     <li>",
"      Karnofsky performance status &lt;70 percent (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ejection fraction &lt;50 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most centers in the United States, patients are considered eligible for myeloablative allogeneic HCT if they are less than 65 years of age, with normal cardiac, liver, and renal function, and in good performance status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70421963\">",
"    <span class=\"h2\">",
"     Conditioning regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal conditioning (preparative) regimen prior to HCT is unknown and clinical practice differs by institution according to experience. The best outcomes appear to be with myeloablative preparative regimens. Nonmyeloablative preparative regimens may be considered for patients who are not candidates for myeloablative HCT, but have attained a CR. Possible options include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Myeloablative regimens",
"      </strong>",
"      &mdash; A myeloablative conditioning regimen consists of a single agent or combination of agents expected to destroy the hematopoietic cells in the bone marrow and produce profound pancytopenia within 1 to 3 weeks from the time of administration. The resulting pancytopenia is long-lasting, usually irreversible, and in most instances fatal, unless hematopoiesis is restored by infusion of hematopoietic stem cells. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link&amp;anchor=H5#H5\">",
"       \"Preparative regimens for hematopoietic cell transplantation\", section on 'Myeloablative preparative regimens'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Examples include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       Busulfan",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       Melphalan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      , and total body irradiation (TBI) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      plus TBI [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/31\">",
"       31",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Nonmyeloablative (reduced intensity) regimens",
"      </strong>",
"      &mdash; A nonmyeloablative regimen is one that combines the anti-leukemia effect of more modest doses of chemotherapy with the objective of achieving significant immunosuppression (to allow engraftment), and thereby causing minimal organ and mucosal damage. &ldquo;Nonmyeloablative&rdquo; is probably not the most appropriate term, since the doses of alkylating agents typically used will result in long period of severe cytopenias prior to marrow recovery. Examples of reduced intensity regimens include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link&amp;anchor=H13#H13\">",
"       \"Preparative regimens for hematopoietic cell transplantation\", section on 'Nonmyeloablative and reduced intensity preparative regimens'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Myeloablative HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival following myeloablative HCT in patients with relapsed AML is &le;35 percent, significantly less than that seen when performed in first complete remission (CR). This is not only because patients are usually sicker after relapse, but also because their leukemia is more resistant to treatment. Thus, transplantation-related mortality is higher and post-transplant relapses are more frequent. However, patients with relapsed or refractory AML represent a heterogeneous population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17274?source=see_link&amp;anchor=H14#H14\">",
"     \"Post-remission therapy for acute myeloid leukemia in younger adults\", section on 'Myeloablative allogeneic transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, a study of 383 adult patients with acute leukemia from nine participating Australian transplant centers, in which progressive disease was responsible for 48 percent of the deaths, yielded the following five-year survival rates for patients with AML receiving myeloablative HCT between 1981 and 1997 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transplanted in untreated first relapse or second CR",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      First CR duration longer than six months &mdash; 35 percent",
"     </li>",
"     <li>",
"      First CR duration less than six months &mdash; 20 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transplanted after primary induction failure &mdash; 15 percent",
"     </li>",
"     <li>",
"      Transplanted in chemotherapy-refractory first relapse or beyond second CR &mdash; 5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The greatest experience with myeloablative HCT for relapsed or refractory disease is provided by a retrospective analysis of 2255 patients with relapsed or refractory leukemia reported to the Center for International Blood and Marrow Transplant Research between 1995 and 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/4\">",
"     4",
"    </a>",
"    ]. This analysis included 1673 patients with primary refractory AML (38 percent), first untreated relapse (19 percent), first refractory relapse (26 percent), first relapse with unknown treatment status (1 percent), or second or additional relapse (17 percent). Overall, the survival rate at three years was 19 percent. Acute graft-versus-host disease (GVHD) was seen in 48 percent of patients with 23 percent experiencing severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    acute GVHD. Chronic GVHD was seen in approximately one-quarter of patients.",
"   </p>",
"   <p>",
"    A pretransplant scoring system was developed using five criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Duration of CR: First CR &le;6 months = 1 point",
"     </li>",
"     <li>",
"      Cytogenetics prior to HCT: Poor risk = 1 point",
"     </li>",
"     <li>",
"      Donor: Mismatched unrelated donor = 1 point; Related donor other than HLA identical sibling = 2 points",
"     </li>",
"     <li>",
"      Circulating blasts: present = 1 point",
"     </li>",
"     <li>",
"      Karnofsky performance status: &lt; 90 = 1 point",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using this point-based system, the total score predicted long-term survival. Rates of three-year overall survival were 42, 28, 15, and 6 percent for patients with 0, 1, 2, and 3 points, respectively.",
"   </p>",
"   <p>",
"    Survival rates may be higher with HCT performed using more modern supportive care. A single-center retrospective analysis of HCT for hematologic malignancy compared outcomes in 1418 patients undergoing first allogeneic HCT from 1993 to 1997 with those of 1148 patients undergoing first allogeneic HCT from 2003 to 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/29\">",
"     29",
"    </a>",
"    ]. There was a substantial reduction in nonrelapse death (26 versus 41 percent) and increased long-term survival (53 versus 37 percent) which appeared to be related to reductions in organ damage, infection, and severe acute graft-versus-host disease. While part of this benefit is likely due to a shift from high-dose myeloablative conditioning regimens to standard myeloablative or reduced intensity conditioning regimens in the latter study period, part of this effect may be due to a change in stem cell source, graft-versus-host disease prophylaxis, and other supportive measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70422035\">",
"    <span class=\"h3\">",
"     Nonmyeloablative (reduced intensity) HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonmyeloablative allogeneic HCT is a potential treatment option for patients with relapsed AML who are not candidates for myeloablative HCT. Case series using matched related or matched unrelated donors have reported transplant-related mortality at one year of 17 to 55 percent, with three- to four-year progression-free survival rates of 19 to 30 percent, depending on the treatment program used [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/34-41\">",
"     34-41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link&amp;anchor=H13#H13\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Nonmyeloablative and reduced intensity preparative regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonmyeloablative HCT has its main role as consolidation therapy in patients who can be successfully induced into a complete remission prior to HCT. This strategy relies in large part upon an immunological graft-versus-leukemia effect rather than a direct cytotoxic effect from the preparative regimen. Because it may take several months for the donor immune system to engraft, expand, and activate, nonmyeloablative HCT is not appropriate for patients with refractory or rapidly progressive AML. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70422195\">",
"    <span class=\"h2\">",
"     Choice of donor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred donor for patients with relapsed or refractory AML undergoing allogeneic HCT is an HLA-matched sibling donor [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/4\">",
"     4",
"    </a>",
"    ]. However, only 25 to 30 percent of potential recipients have HLA-matched siblings who can serve as donors. With the advent of molecular typing techniques, morbidity and mortality associated with the use of HLA-matched unrelated donors has declined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H13#H13\">",
"     \"Donor selection for hematopoietic cell transplantation\", section on 'Matched unrelated donors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients without an HLA-matched sibling, the following donors may be considered (listed in order of preference) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/4,32,42-51\">",
"     4,32,42-51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Well matched unrelated donor",
"     </li>",
"     <li>",
"      Partially matched unrelated donor (ie,",
"      <span class=\"nowrap\">",
"       9/10",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       8/10",
"      </span>",
"      matches)",
"     </li>",
"     <li>",
"      Single antigen mismatched related donor",
"     </li>",
"     <li>",
"      Umbilical cord blood transplantation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Allogeneic HCT using a matched unrelated donor (MUD) is an option for younger adults who lack a sibling donor. The likelihood of finding a MUD in the National Bone Marrow Donor Registry is related in part to the ethnic background of the patient compared with the volunteer donor pool. It also depends on the number of allelic mismatches between donor and recipient that one wishes to allow (eg, a full",
"    <span class=\"nowrap\">",
"     10/10",
"    </span>",
"    match or",
"    <span class=\"nowrap\">",
"     9/10",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     8/10",
"    </span>",
"    with mismatches). The overall match rate is approximately 50 percent for Caucasians but only 10 percent for minorities who are both under-represented in the donor pool and more polymorphic with respect to HLA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/52\">",
"     52",
"    </a>",
"    ]. Outcomes after a well-matched unrelated donor (ie,",
"    <span class=\"nowrap\">",
"     10/10",
"    </span>",
"    match) approach those seen with an HLA-matched sibling donor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17274?source=see_link&amp;anchor=H16#H16\">",
"     \"Post-remission therapy for acute myeloid leukemia in younger adults\", section on 'Choice of donor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the relative immaturity of the immune system in umbilical cord samples, stem cells from this source allow the crossing of immunologic barriers that would otherwise be prohibitive. As a result, the degree of HLA-disparity that is tolerable is much greater, making this approach more feasible for members of minorities. In addition, cord blood has already been collected and cryopreserved before the time a match is identified, thereby greatly reducing the time required for accessing the donor and completing the transplant procedure; however, there is less clinical follow-up with cord blood transplantations and long term follow-up will be necessary to determine whether they truly provide equivalent results [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/47,53\">",
"     47,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link&amp;anchor=H63572418#H63572418\">",
"     \"Sources of hematopoietic stem cells\", section on 'Umbilical cord blood'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For adult patients with leukemia, there appear to be no significant differences in the rate of recurrence, treatment-related mortality, treatment failure, or overall mortality between those receiving HCT with mismatched marrow or mismatched umbilical cord blood [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/45,54\">",
"     45,54",
"    </a>",
"    ]. As an example, one study examined unrelated cord blood HCT in 14 patients, most of whom had advanced de novo AML (one primary induction failure, seven in relapse, and six beyond first CR) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/55\">",
"     55",
"    </a>",
"    ]. Although all donors were mismatched at at least one locus, and acute and chronic GVHD were common complications, 17 of the 18 patients had myeloid reconstitution, with a two-year probability of disease-free survival of 77 percent.",
"   </p>",
"   <p>",
"    As with nonmyeloablative HCT, cord blood HCT has its main role as consolidation therapy in patients who can be successfully induced into a complete remission prior to transplant. The reduced numbers of stem cells available from cord blood collections may limit the usefulness of this procedure in larger adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15865?source=see_link&amp;anchor=H61604465#H61604465\">",
"     \"Selection of an umbilical cord blood graft for hematopoietic cell transplantation\", section on 'Cord blood as a resource'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Haploidentical donors are considered investigational in this setting as only limited data in selected patients are available and this procedure is associated with severe and prolonged immunodeficiency after transplantation. This method uses T-cell depleted stem cells from related donors with one fully mismatched HLA haplotype, sometimes called partially-matched family member transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. A retrospective analysis that included 46 patients who underwent haploidentical HCT in second CR reported rates of treatment related mortality, relapse, and leukemia-free survival of 54, 23, and 21 percent, respectively after a median follow-up of 47 months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/57\">",
"     57",
"    </a>",
"    ]. This analysis also included 87 patients with AML who underwent haploidentical HCT while in relapse. These high risk patients had a rate of leukemia free survival of only 1 percent. This procedure had a high incidence of treatment related mortality (66 percent) and leukemia relapse (32 percent) in this population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RELAPSE AFTER HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of hematopoietic cell transplant (HCT) recipients experiencing AML relapse is a controversial issue. The median survival of patients relapsing after an allogeneic HCT is only three to four months if no further therapy were given [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/58\">",
"     58",
"    </a>",
"    ]. The only therapies that have a potential for cure in these patients are a second transplant or donor lymphocyte infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/59\">",
"     59",
"    </a>",
"    ]. Patients who relapse more than one year after HCT may benefit from a second HCT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Second HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second allograft offers a chance of long-term leukemia free survival in selected patients. Only a limited proportion of patients are well enough for such intensive treatment, and the treatment related mortality is high (25 to 50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. The relapse rate is also high. Leukemia-free survival rates at three to five years range from 11 to 42 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/60-63\">",
"     60-63",
"    </a>",
"    ]. Prognostic variables associated with a poor outcome include a short interval between initial transplant and relapse (especially if the interval is less than one year), occurrence of graft-versus-host disease (GVHD) after the first transplant, older age, poor performance status and the lack of remission at the time of second allograft [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. In one study, for example, leukemia-free survival at three years was 52 percent for a subset of patients who relapsed &gt;292 days after the first transplant and who were in remission before receiving the second transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A French cooperative study investigated the efficacy of a second HCT following graft failure or relapse in patients with AML, ALL, or CML [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/64\">",
"     64",
"    </a>",
"    ]. Transplant-related mortality and five-year overall survival were 45 and 32 percent, respectively. Factors associated with a better outcome after the second HCT were age &lt;16 at second HCT, relapse &gt;12 months after first transplant, female donor, absence of acute GVHD, and occurrence of chronic GVHD.",
"   </p>",
"   <p>",
"    A number of suggestions have been made to improve outcome in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients who might be candidates for a second HCT should receive reinduction chemotherapy first; only those responding to treatment (usually no more than 50 percent) should proceed to a second transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/59\">",
"       59",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GVHD prophylaxis should be reduced after the second HCT to maximize the graft-versus-leukemia (GVL) effect [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/59\">",
"       59",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44729?source=see_link\">",
"       \"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Relapsing patients may receive a second transplant following reduced intensity conditioning. In one series, seven patients with AML relapsing after an allograft were treated with the FLAG regimen (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      , high dose Ara-C, G-CSF) with or without an anthracycline, followed by a second allogeneic HCT from the original donor [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/65\">",
"       65",
"      </a>",
"      ]. Complete remission was attained in six with no treatment-related mortality. Median duration of the second CR was 14 months, which was slightly longer than the first CR of 11 months. Chronic GVHD was extensive in four of the seven.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Donor lymphocyte infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discontinuation of immunosuppression followed by donor lymphocyte infusion (DLI) induces remission in 20 to 35 percent of patients who relapse after allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/59,66-68\">",
"     59,66-68",
"    </a>",
"    ]. This can only be done if there is no ongoing active GVHD. It has been suggested that DLI is most effective in patients with minimal residual disease in whom the graft-versus-leukemia effect would likely be most effective [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/59\">",
"     59",
"    </a>",
"    ]. DLI may be also considered as a means of T-cell repletion for the prevention of leukemia recurrence in patients given a T-cell depleted HCT from a compatible sibling [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16298?source=see_link&amp;anchor=H3#H3\">",
"     \"Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation\", section on 'Donor lymphocyte infusions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All data on DLI are based on retrospective studies, the largest of which was a cohort of 399 patients with AML in first hematological relapse after HCT who did or did not receive a DLI [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/69\">",
"     69",
"    </a>",
"    ]. At a median follow-up of over 27 months, the following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two-year overall survival rates were significantly higher in those patients who received a DLI (21 versus 9 percent, respectively).",
"     </li>",
"     <li>",
"      Patients more likely to have a good response to DLI included those with favorable cytogenetics, those with a hematological remission prior to DLI, and those with a lower tumor burden (less than 35 percent blasts in bone marrow) at relapse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Randomized studies are needed to demonstrate a true advantage of DLI. The use of DLI remains an individualized decision based upon patient age, cytogenics, and tumor burden. DLI is unlikely to be effective in patients with relapsed leukemia that no longer expresses the mismatched HLA antigen thought to be responsible for the graft-versus-leukemia effect [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21583133\">",
"    <span class=\"h1\">",
"     PROGNOSTIC INDICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, patients with relapsed or refractory AML are a heterogenous population with long-term survival rates after allogeneic hematopoietic cell transplantation (HCT) ranging from 40 percent to less than 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Several prognostic scoring systems have been developed to predict outcomes in this population.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       First relapse",
"      </strong>",
"      &mdash; A European Prognostic Index (EPI) was developed based on results in 667 patients with AML in first relapse among 1540 newly diagnosed patients with AML (age 15 to 60 years) entered onto Dutch-, Belgian-, and Swiss-collaborative group trials [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/5\">",
"       5",
"      </a>",
"      ]. The following four risk factors (with accompanying point scores) were found on multivariate analysis:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Relapse-free interval from first complete remission (0, 3, and 5 points for &gt;18, 7 to 18, and &le;6 months, respectively)",
"     </li>",
"     <li>",
"      Cytogenetics at the time of diagnosis (0, 3, and 5 points for t(16;16) or Inv(16); t(8;21) with or without other abnormalities, and normal, intermediate, unfavorable, or unknown cytogenetics, respectively)",
"     </li>",
"     <li>",
"      Age at first relapse (0, 1, and 2 points for &le;35, 36 to 45, and &gt;45 years, respectively)",
"     </li>",
"     <li>",
"      Autologous or allogeneic hematopoietic cell transplantation (HCT) before first relapse (0 and 2 points for no prior HCT or a prior HCT, respectively)",
"      <br/>",
"      <br/>",
"      Three risk groups were identified: favorable (1 to 6 points), intermediate (7 to 9 points), and high risk (10 to 14 points), with five-year overall survival rates of 22 to 46, 12 to 18, and 4 to 6 percent, respectively, when the EPI was employed by two different groups [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Second salvage therapy",
"      </strong>",
"      &mdash; In a retrospective single center study of 594 patients with AML undergoing a second salvage treatment that included conventional or experimental therapies or HCT, the median survival was only 1.5 months and the one-year survival 8 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/71\">",
"       71",
"      </a>",
"      ]. Thirteen percent of patients achieved a complete remission (CR) and their median CR duration was seven months. On multivariate analysis, the following factors adversely affected overall survival:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      First CR duration &lt;12 months",
"     </li>",
"     <li>",
"      Second CR duration &lt;6 months",
"     </li>",
"     <li>",
"      Serum bilirubin level &ge;1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      Serum albumin level &lt;3",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Age &gt;60 years",
"     </li>",
"     <li>",
"      Bone marrow blasts &ge;50 percent",
"     </li>",
"     <li>",
"      Year of therapy before 1991",
"      <br/>",
"      <br/>",
"      Patients at low-risk (zero to two adverse factors), intermediate risk (three adverse factors), or high-risk (&ge;four adverse factors) had estimated one-year survival rates of 22, 6, and zero percent, respectively. The rates of CR within the same risk groups were 26, 8, and 2 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Patients without CR before HCT",
"      </strong>",
"      &mdash; A retrospective analysis from the Center for International Blood and Marrow Transplant Research included 1673 patients with relapsed or refractory AML between 1995 and 2004 [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/4\">",
"       4",
"      </a>",
"      ]. This analysis included 1673 patients with primary refractory AML (38 percent), first untreated relapse (19 percent), first refractory relapse (26 percent), first relapse with unknown treatment status (1 percent), or second or additional relapse (17 percent). Overall, the survival rate at three years was 19 percent.",
"      <br/>",
"      <br/>",
"      A pretransplant scoring system was developed using five criteria [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/4\">",
"       4",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Duration of CR: First CR &le;6 months = 1 point",
"     </li>",
"     <li>",
"      Cytogenetics prior to HCT: Poor risk = 1 point",
"     </li>",
"     <li>",
"      Donor: Mismatched unrelated donor = 1 point; Related donor other than HLA identical sibling = 2 points",
"     </li>",
"     <li>",
"      Circulating blasts: present = 1 point",
"     </li>",
"     <li>",
"      Karnofsky performance status: &lt; 90 = 1 point",
"      <br/>",
"      <br/>",
"      Using this point-based system, the total score predicted long-term survival. Rates of three-year overall survival were 42, 28, 15, and 6 percent for patients with 0, 1, 2, and 3 points, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70421931\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Experimental agents or protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients failing all conventional drug protocols may elect to undergo experimental treatment with investigational agents or protocols [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/72-81\">",
"     72-81",
"    </a>",
"    ]. Although response rates are presented for some of these regimens, an individual&rsquo;s chance of responding to a particular regimen is influenced not only by prior exposure to chemotherapy but also by other patient- and leukemia-associated factors. A preferred regimen would exclude agents at dose levels for salvage which the patient has been exposed to recently.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      trials of the nucleoside analog",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/5/33879?source=see_link\">",
"       clofarabine",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      IV daily for five days every three to six weeks), with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      , in patients with",
"      <span class=\"nowrap\">",
"       relapsed/refractory",
"      </span>",
"      AML have yielded complete remission rates of 28 to 42 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/82,83\">",
"       82,83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tipifarnib (Zarnestra), an orally active inhibitor of farnesyl protein transferase [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/84,85\">",
"       84,85",
"      </a>",
"      ], has achieved clinical responses in patients with refractory and relapsed poor-risk AML and has undergone initial studies as maintenance therapy after first complete remission in patients with poor risk features [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/86-89\">",
"       86-89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"       Decitabine",
"      </a>",
"      (5-aza-2'-deoxycytidine), a pyrimidine nucleoside analog of cytidine, strongly inhibits DNA methylation and induces cell differentiation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/90\">",
"       90",
"      </a>",
"      ]. A response rate of 44 percent was reported in a phase I study of decitabine alone or in combination with valproic acid [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/91\">",
"       91",
"      </a>",
"      ]. Valproic acid did not appear to increase response rates and led to encephalopathy at relatively low doses.",
"     </li>",
"     <li>",
"      A phase II trial explored the utility of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      (Avastin), an anti-VEGF monoclonal antibody, along with chemotherapy (sequential 1-beta-D-arabinofuranosylcytosine and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      ) in 48 patients with relapsed or refractory AML [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/92\">",
"       92",
"      </a>",
"      ]. Overall and complete remission rates were 48 and 33 percent, respectively. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=see_link&amp;anchor=H20#H20\">",
"       \"Overview of angiogenesis inhibitors\", section on 'Anti-VEGF neutralizing antibodies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A phase I trial in 41 patients with heavily pretreated relapsed or refractory leukemia (37 of whom had AML) identified",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/29/27093?source=see_link\">",
"       vorinostat",
"      </a>",
"      (400 mg TID for 3 days) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"       idarubicin",
"      </a>",
"      (12",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      daily for 3 days) as a regimen with good tolerability [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/93\">",
"       93",
"      </a>",
"      ]. Clinical responses were seen in six of the patients with AML, including two complete remissions.",
"     </li>",
"     <li>",
"      Lintuzumab is an unconjugated humanized murine monoclonal antibody directed against CD33. It was employed in a randomized phase III study in 191 patients with refractory or relapsed AML, which utilized combination chemotherapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ) with or without lintuzumab [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/94\">",
"       94",
"      </a>",
"      ]. While the addition of this agent to salvage chemotherapy was safe, it did not result in significant improvement in response rate or survival.",
"     </li>",
"     <li>",
"      A phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      study of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      (MEC) in combination with the CXCR4 antagonist",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/12/27844?source=see_link\">",
"       plerixafor",
"      </a>",
"      in 52 patients with relapsed and refractory AML reported a complete remission rate of 39 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/95\">",
"       95",
"      </a>",
"      ]. Plerixafor is known to disrupt the adhesion between myeloblasts and the bone marrow stroma. The hypothesis being explored with this combination of agents states that AML cells released into the circulation will be more susceptible to the lethal effects of chemotherapy than if they remained in their bone marrow niche.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21585075\">",
"    <span class=\"h2\">",
"     Gemtuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/3/1078?source=see_link\">",
"     Gemtuzumab ozogamicin",
"    </a>",
"    (CMA-676, Mylotarg) is an anti-CD33 antibody linked to calicheamicin, a potent cytotoxic agent. The drug appears to be rapidly and specifically targeted to CD33+ cells, followed by internalization and subsequent induction of cell death [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/96\">",
"     96",
"    </a>",
"    ]. The in vitro and in vivo effectiveness of this agent appears to be reduced in the presence of high levels of P-glycoprotein expression and function [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/97,98\">",
"     97,98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gemtuzumab was approved by the FDA for use in patients age 60 or older with CD33+ AML in first relapse who are not considered candidates for cytotoxic chemotherapy at a dose of 9",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    given by two-hour IV infusion, with a second dose two weeks later [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. This was based upon initial studies demonstrating superior complete remission rates and overall survival for patients with CD33+ AML in untreated first relapse who received gemtuzumab [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/99,101-104\">",
"     99,101-104",
"    </a>",
"    ]. The US Food and Drug Administration has since required that gemtuzumab be removed from the market in the United States because subsequent randomized trials did not confirm a clinical benefit for newly diagnosed patients with AML when it was combined with standard chemotherapy. Further studies of gemtuzumab in specific patient populations are continuing in the US.",
"   </p>",
"   <p>",
"    Studies are underway to determine if there is a role for gemtuzumab in the management in a subset of patients. The use of gemtuzumab in newly diagnosed AML is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=see_link&amp;anchor=H732965#H732965\">",
"     \"Treatment of acute myeloid leukemia in older adults\", section on 'Gemtuzumab ozogamicin (GO)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infusion-related toxicity (fever, chills, hypotension, shortness of breath, and abnormal liver function tests) is appreciable, but transient. However, grade 3 or 4 neutropenia and thrombocytopenia occurs in all patients. Mucositis and diarrhea are uncommon. In addition, postmarketing reports described a number of serious adverse reactions, including fatal anaphylaxis, prolonged thrombocytopenia, hepatic damage including sinusoidal obstruction syndrome (also called hepatic veno-occlusive disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/51/29498/abstract/105-108\">",
"     105-108",
"    </a>",
"    ], acute respiratory distress syndrome, and tumor lysis syndrome with ARDS in patients with a white blood cell count",
"    <span class=\"nowrap\">",
"     &gt;30,000/microL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/30/34275?source=see_link\">",
"       \"Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21583063\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty to 50 percent of adult patients with newly diagnosed acute myeloid leukemia (AML) will fail to attain a complete remission (CR) with intensive induction chemotherapy (primary refractory). In addition, a large percentage of patients who initially attain a CR will later have relapsed disease. (See",
"      <a class=\"local\" href=\"#H261038589\">",
"       'Definitions of relapse and refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients suspected of having relapsed AML should be evaluated with a unilateral bone marrow aspiration: a trephine biopsy provides additional information and is required if the aspiration sample is poor. Once relapsed or refractory disease is identified, further evaluation should include assessments of performance status and organ function. HLA typing should be done to initiate a donor search for hematopoietic cell transplantation (HCT). (See",
"      <a class=\"local\" href=\"#H21582911\">",
"       'Evaluation of suspected relapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The therapy with the greatest chance of cure for a patient with relapsed or refractory AML is an allogeneic HCT. However, there have been long term survivors after autologous HCT, too. Not all patients will require additional induction chemotherapy prior to myeloablative HCT while all patients undergoing a nonmyeloablative HCT should undergo further induction chemotherapy in order to attain a CR prior to HCT, if possible. Consultation with a physician who specializes in HCT should take place at the time refractory or relapsed disease is identified to help with the decision process and timing. Patients who are not candidates for transplantation should be considered for clinical trials with investigational agents. (See",
"      <a class=\"local\" href=\"#H261041554\">",
"       'Selection of therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Eligibility for allogeneic HCT varies across countries and institutions. In most centers in the United States, factors that make a patient ineligible for myeloablative HCT include poor overall performance status or evidence of moderate to severe impairment of pulmonary, liver, kidney, or cardiac function. (See",
"      <a class=\"local\" href=\"#H70422874\">",
"       'Determining transplant eligibility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ideal conditioning (preparative) regimen prior to HCT is not known and clinical practice differs by institution according to experience. For most patients with relapsed or refractory AML undergoing HCT, we recommend the use of a myeloablative conditioning regimen (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Nonmyeloablative or reduced intensity conditioning regimens should be considered for patients who are not candidates for myeloablative HCT, but have attained a marrow remission.",
"     </li>",
"     <li>",
"      The preferred donor for patients with relapsed or refractory AML undergoing allogeneic HCT is an HLA-matched sibling donor. If no sibling donor can be identified, an alternative donor search (including cord blood) should be initiated. If no donor is available, an autologous stem cell transplant might be a possibility in highly selected circumstances. (See",
"      <a class=\"local\" href=\"#H70422195\">",
"       'Choice of donor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal management of hematopoietic cell transplant (HCT) recipients experiencing AML relapse is a controversial issue. The only therapies that have a potential for cure in these patients are a second transplant or donor lymphocyte infusion. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Relapse after HCT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with relapsed or refractory AML are a heterogenous population with long-term survival rates after allogeneic HCT ranging from 40 percent to less than 5 percent. Several prognostic scoring systems have been developed to predict outcomes in this population. (See",
"      <a class=\"local\" href=\"#H21583133\">",
"       'Prognostic indices'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/1\">",
"      Rowe JM, Kim HT, Cassileth PA, et al. Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Cancer 2010; 116:5012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/2\">",
"      Bachas C, Schuurhuis GJ, Hollink IH, et al. High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. Blood 2010; 116:2752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/3\">",
"      Rowe JM, Tallman MS. How I treat acute myeloid leukemia. Blood 2010; 116:3147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/4\">",
"      Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010; 28:3730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/5\">",
"      Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005; 23:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/6\">",
"      Giles F, Verstovsek S, Garcia-Manero G, et al. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol 2006; 134:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/7\">",
"      Herzig RH, Lazarus HM, Wolff SN, et al. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol 1985; 3:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/8\">",
"      Karanes C, Kopecky KJ, Head DR, et al. A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study. Leuk Res 1999; 23:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/9\">",
"      Ho AD, Lipp T, Ehninger G, et al. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen. J Clin Oncol 1988; 6:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/10\">",
"      Daenen S, L&ouml;wenberg B, Sonneveld P, et al. Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON). Leukemia 1994; 8:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/11\">",
"      Rowe JM, Mazza JJ, Hines JD, et al. Mitoxantrone and etoposide in patients with relapsed and refractory acute nonlymphocytic leukemia. Haematol Blood Transfus 1990; 33:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/12\">",
"      Amadori S, Arcese W, Isacchi G, et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol 1991; 9:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/13\">",
"      B&uuml;chner T, Hiddemann W, W&ouml;rmann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999; 93:4116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/14\">",
"      Bergmann L, Heil G, Denzlinger C, et al. Triple combination of mitoxantrone, topotecan, araC (MTC) in relapsed or refractory AML (abstract). Proc ASCO 2002; 21:271a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/15\">",
"      Sternberg DW, Aird W, Neuberg D, et al. Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen. Cancer 2000; 88:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/16\">",
"      Montillo M, Mirto S, Petti MC, et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol 1998; 58:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/17\">",
"      Jackson G, Taylor P, Smith GM, et al. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol 2001; 112:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/18\">",
"      Martin MG, Welch JS, Augustin K, et al. Cladribine in the treatment of acute myeloid leukemia: a single-institution experience. Clin Lymphoma Myeloma 2009; 9:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/19\">",
"      Wierzbowska A, Robak T, Pluta A, et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol 2008; 80:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/20\">",
"      Brown RA, Herzig RH, Wolff SN, et al. High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood 1990; 76:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/21\">",
"      Liu Yin JA, Wheatley K, Rees JK, et al. Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol 2001; 113:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/22\">",
"      Cortes J, Estey E, O'Brien S, et al. High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer 2001; 92:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/23\">",
"      Fassas A, Buffels R, Anagnostopoulos A, et al. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study. Br J Haematol 2002; 116:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/24\">",
"      Chevallier P, Delaunay J, Turlure P, et al. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. J Clin Oncol 2008; 26:5192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/25\">",
"      Becker PS, Kantarjian HM, Appelbaum FR, et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol 2011; 155:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/26\">",
"      Scappini B, Gianfaldoni G, Caracciolo F, et al. Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients. Am J Hematol 2012; 87:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/27\">",
"      Chantry AD, Snowden JA, Craddock C, et al. Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study. Biol Blood Marrow Transplant 2006; 12:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/28\">",
"      McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010; 28:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/29\">",
"      Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/30\">",
"      Murata M, Nishida T, Haneda M, et al. A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation. Br J Haematol 1999; 105:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/31\">",
"      Bacigalupo A, Vitale V, Corv&ograve; R, et al. The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation. Br J Haematol 2000; 108:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/32\">",
"      Ringd&eacute;n O, Labopin M, Ehninger G, et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27:4570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/33\">",
"      Grigg AP, Szer J, Beresford J, et al. Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. Br J Haematol 1999; 107:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/34\">",
"      Wong R, Giralt SA, Martin T, et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 2003; 102:3052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/35\">",
"      de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/36\">",
"      Kobayashi K, Kami M, Murashige N, et al. Outcomes of patients with acute leukaemia who relapsed after reduced-intensity stem cell transplantation from HLA-identical or one antigen-mismatched related donors. Br J Haematol 2005; 129:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/37\">",
"      Claxton DF, Ehmann C, Rybka W. Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation. Br J Haematol 2005; 130:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/38\">",
"      Schmid C, Schleuning M, Ledderose G, et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23:5675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/39\">",
"      van Besien K, Artz A, Smith S, et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23:5728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/40\">",
"      Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23:9387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/41\">",
"      Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/42\">",
"      Moore J, Nivison-Smith I, Goh K, et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2007; 13:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/43\">",
"      Valcarcel D, Kan F, Wang T, et al. One antigen HLA-mismatched related and 8/8 allele matched unrelated donors are associated with similar survival after hematopoietic cell transplantation for acute leukemia (abstract). Blood 2008; 112:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/44\">",
"      Appelbaum FR. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia when a matched related donor is not available. Hematology Am Soc Hematol Educ Program 2008; :412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/45\">",
"      Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/46\">",
"      Schetelig J, Bornh&auml;user M, Schmid C, et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol 2008; 26:5183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/47\">",
"      Atsuta Y, Suzuki R, Nagamura-Inoue T, et al. Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood 2009; 113:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/48\">",
"      Basara N, Schulze A, Wedding U, et al. Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. Leukemia 2009; 23:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/49\">",
"      Walter RB, Pagel JM, Gooley TA, et al. Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. Leukemia 2010; 24:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/50\">",
"      Gupta V, Tallman MS, He W, et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood 2010; 116:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/51\">",
"      Saber W, Opie S, Rizzo JD, et al. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood 2012; 119:3908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/52\">",
"      Mori M, Beatty PG, Graves M, et al. HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry. Transplantation 1997; 64:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/53\">",
"      Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010; 11:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/54\">",
"      Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351:2265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/55\">",
"      Ooi J, Iseki T, Takahashi S, et al. Unrelated cord blood transplantation for adult patients with de novo acute myeloid leukemia. Blood 2004; 103:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/56\">",
"      Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23:3447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/57\">",
"      Ciceri F, Labopin M, Aversa F, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008; 112:3574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/58\">",
"      Frassoni F, Barrett AJ, Gra&ntilde;ena A, et al. Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases. Br J Haematol 1988; 70:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/59\">",
"      Locatelli F. The role of repeat transplantation of haemopoietic stem cells and adoptive immunotherapy in treatment of leukaemia relapsing following allogeneic transplantation. Br J Haematol 1998; 102:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/60\">",
"      Radich JP, Sanders JE, Buckner CD, et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 1993; 11:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/61\">",
"      Barrett AJ, Locatelli F, Treleaven JG, et al. Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party. Br J Haematol 1991; 79:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/62\">",
"      Bosi A, Laszlo D, Labopin M, et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2001; 19:3675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/63\">",
"      Bosi A, Bacci S, Miniero R, et al. Second allogeneic bone marrow transplantation in acute leukemia: a multicenter study from the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). Leukemia 1997; 11:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/64\">",
"      Michallet M, Tanguy ML, Soci&eacute; G, et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Soci&eacute;t&eacute; Fran&ccedil;aise de Greffe de moelle (SFGM). Br J Haematol 2000; 108:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/65\">",
"      Pawson R, Potter MN, Theocharous P, et al. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant. Br J Haematol 2001; 115:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/66\">",
"      Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/67\">",
"      Verdonck LF, Petersen EJ, Lokhorst HM, et al. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. Bone Marrow Transplant 1998; 22:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/68\">",
"      Schmid C, Labopin M, Nagler A, et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood 2012; 119:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/69\">",
"      Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007; 25:4938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/70\">",
"      Vago L, Perna SK, Zanussi M, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 2009; 361:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/71\">",
"      Giles F, O'Brien S, Cortes J, et al. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer 2005; 104:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/72\">",
"      Giles FJ, Faderl S, Thomas DA, et al. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol 2003; 21:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/73\">",
"      Roboz GJ, Giles FJ, Ritchie EK, et al. Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia. J Clin Oncol 2007; 25:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/74\">",
"      Thomas DA, Estey E, Giles FJ, et al. Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. Br J Haematol 2003; 123:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/75\">",
"      Ravandi F, Kantarjian H, Giles F, Cortes J. New agents in acute myeloid leukemia and other myeloid disorders. Cancer 2004; 100:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/76\">",
"      Aribi A, Ravandi F, Giles F. Novel agents in acute myeloid leukemia. Cancer J 2006; 12:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/77\">",
"      Kolitz JE. Current therapeutic strategies for acute myeloid leukaemia. Br J Haematol 2006; 134:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/78\">",
"      Fehniger TA, Byrd JC, Marcucci G, et al. Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood 2009; 113:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/79\">",
"      Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009; 113:6567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/80\">",
"      Schimmer AD, Estey EH, Borthakur G, et al. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol 2009; 27:4741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/81\">",
"      Cortes J, Kantarjian H, Ball ED, et al. Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer 2012; 118:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/82\">",
"      Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003; 102:2379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/83\">",
"      Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005; 105:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/84\">",
"      Lancet JE, Karp JE. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood 2003; 102:3880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/85\">",
"      Armand JP, Burnett AK, Drach J, et al. The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib. Oncologist 2007; 12:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/86\">",
"      Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001; 97:3361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/87\">",
"      Harousseau JL, Lancet JE, Reiffers J, et al. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood 2007; 109:5151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/88\">",
"      Karp JE, Smith BD, Gojo I, et al. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res 2008; 14:3077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/89\">",
"      Karp JE, Vener TI, Raponi M, et al. Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood 2012; 119:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/90\">",
"      Fandy TE, Carraway H, Gore SD. DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies. Cancer J 2007; 13:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/91\">",
"      Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007; 25:3884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/92\">",
"      Karp JE, Gojo I, Pili R, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res 2004; 10:3577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/93\">",
"      Kadia TM, Yang H, Ferrajoli A, et al. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol 2010; 150:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/94\">",
"      Feldman EJ, Brandwein J, Stone R, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 2005; 23:4110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/95\">",
"      Uy GL, Rettig MP, Motabi IH, et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012; 119:3917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/96\">",
"      van Der Velden VH, te Marvelde JG, Hoogeveen PG, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001; 97:3197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/97\">",
"      Linenberger ML, Hong T, Flowers D, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 2001; 98:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/98\">",
"      Walter RB, Gooley TA, van der Velden VH, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007; 109:4168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/99\">",
"      Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/100\">",
"      Gemtuzumab for relapsed acute myeloid leukemia. Med Lett Drugs Ther 2000; 42:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/101\">",
"      Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19:3244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/102\">",
"      Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005; 104:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/103\">",
"      Arceci RJ, Sande J, Lange B, et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood 2005; 106:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/104\">",
"      Aplenc R, Alonzo TA, Gerbing RB, et al. Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Clin Oncol 2008; 26:2390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/105\">",
"      Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002; 99:2310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/106\">",
"      Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001; 92:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/107\">",
"      Stadtmauer EA. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Curr Oncol Rep 2002; 4:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/51/29498/abstract/108\">",
"      Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003; 102:1578.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4540 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-190.92.87.104-00AB8D06A0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_51_29498=[""].join("\n");
var outline_f28_51_29498=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21583063\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H625274\">",
"      EVALUATION FOR RELAPSE OR RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H261038589\">",
"      Definitions of relapse and refractory disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21582911\">",
"      Evaluation of suspected relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H261041554\">",
"      SELECTION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21584407\">",
"      HEMATOPOIETIC CELL TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70422874\">",
"      Determining transplant eligibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70421963\">",
"      Conditioning regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Myeloablative HCT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H70422035\">",
"      - Nonmyeloablative (reduced intensity) HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70422195\">",
"      Choice of donor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RELAPSE AFTER HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Second HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Donor lymphocyte infusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21583133\">",
"      PROGNOSTIC INDICES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70421931\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Experimental agents or protocols",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21585075\">",
"      Gemtuzumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21583063\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4540\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4540|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 1\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 2\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/19/32061\" title=\"table 3\">",
"      Chemo regimens relapsed or refractory AML",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44729?source=related_link\">",
"      Biology of the graft-versus-tumor effect following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19974?source=related_link\">",
"      Evaluation for infection before hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16298?source=related_link\">",
"      Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=related_link\">",
"      Overview of angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/30/34275?source=related_link\">",
"      Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17274?source=related_link\">",
"      Post-remission therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36730?source=related_link\">",
"      Prognosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=related_link\">",
"      Remission criteria in acute myeloid leukemia and monitoring for residual disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15865?source=related_link\">",
"      Selection of an umbilical cord blood graft for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=related_link\">",
"      Treatment of acute myeloid leukemia in older adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_51_29499="Pathophysiology respiratory failure in neuromuscular disease";
var content_f28_51_29499=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pathophysiology of neuromuscular respiratory failure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Inadequate ventilation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hypoxemia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ineffective cough",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk for aspiration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inspiratory muscle weakness*",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Expiratory muscle weakness",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Upper airway muscle weakness",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Inspiratory muscles: diaphgragm, external intercostals, scalenes, sternocleidomastoids, trapezii.",
"     <br>",
"      &bull; Expiratory muscles: abdominals (internal and external oblique, rectus abdominus, transverse abdominus), internal intercostals.",
"      <br>",
"       &Delta; Upper airway muscles: abductors and adductors (pharyngeal, laryngeal).",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_51_29499=[""].join("\n");
var outline_f28_51_29499=null;
var title_f28_51_29500="SLE presentation";
var content_f28_51_29500=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency of presenting clinical features of children with systemic lupus erythematosus at tertiary care centers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Clinical features",
"      </td>",
"      <td class=\"subtitle1\">",
"       France, percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Toronto, percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Hematologic",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       72",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       55",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Anemia (Hgb level &le;12 g/dL)",
"      </td>",
"      <td class=\"sublist_other\">",
"       27",
"      </td>",
"      <td class=\"sublist_other\">",
"       NA",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Leukopenia (WBC 4,000/mL)",
"      </td>",
"      <td class=\"sublist_other\">",
"       35",
"      </td>",
"      <td class=\"sublist_other\">",
"       NA",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Lymphopenia",
"      </td>",
"      <td class=\"sublist_other\">",
"       NA",
"      </td>",
"      <td class=\"sublist_other\">",
"       29",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Thrombocytopenia (150,000/mL)",
"      </td>",
"      <td class=\"sublist_other\">",
"       28",
"      </td>",
"      <td class=\"sublist_other\">",
"       29",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Mucocutaneous (eg, rash and oral ulcers)",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       70",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       NA",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Malar rash",
"      </td>",
"      <td class=\"sublist_other\">",
"       39",
"      </td>",
"      <td class=\"sublist_other\">",
"       61",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Musculoskeletal (arthritis, arthralgia)",
"      </td>",
"      <td>",
"       64",
"      </td>",
"      <td>",
"       61",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fever",
"      </td>",
"      <td>",
"       58",
"      </td>",
"      <td>",
"       39",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Renal",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       50",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       NA",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Nephritis",
"      </td>",
"      <td class=\"sublist_other\">",
"       NA",
"      </td>",
"      <td class=\"sublist_other\">",
"       37",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Nephrotic Syndrome",
"      </td>",
"      <td class=\"sublist_other\">",
"       NA",
"      </td>",
"      <td class=\"sublist_other\">",
"       22",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Abdominal complaints",
"      </td>",
"      <td>",
"       26",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NA: data not available.",
"    </div>",
"    <div class=\"reference\">",
"     1. Bader-Meunier, B, Armengaud, JB, Haddad, E, et al. Initial presentation of childhood-onset systemic lupus erythematosus: a French multicenter study. J Pediatr 2005; 146:648.",
"     <br>",
"      2. Hiraki, LT, Benseler, SM, Tyrrell, PN, et al. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr 2008; 152:550.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_51_29500=[""].join("\n");
var outline_f28_51_29500=null;
var title_f28_51_29501="Drug and toxin related skin findings";
var content_f28_51_29501=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug- and toxin-induced skin abnormalities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Red and flushed",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Anticholinergic agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Antihistamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            TCAs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Atropine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Scopolamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Belladonna alkaloids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Phenothiazines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Boric acid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Disulfiram reaction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Disulfiram/ethanol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cephalosporins/ethanol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Solvents/ethanol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Coprinus mushrooms/ethanol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Monosodium glutamate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Scombroid fish poisoning",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rifampin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbon monoxide (rare)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Pale and diaphoretic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Sympathomimetics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Amphetamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Theophylline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Caffeine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ephedrine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Phenylpropanolamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cathinones",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Cholinergic agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Organophosphates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Carbamates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Nerve agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Central hallucinogens",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Lysergic acid diethylamide (LSD)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Phencyclidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Mescaline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Psilocybin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Designer amphetamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Synthetic cannabinoids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Arsenic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Salicylates",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Cyanotic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methemoglobinemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfhemoglobinemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypoxemia",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Desquamation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stevens-Johnson syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Toxic epidermal necrolysis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Boric acid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Heavy metals",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Arsenic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Mercury",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Thallium",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_51_29501=[""].join("\n");
var outline_f28_51_29501=null;
var title_f28_51_29502="Diagnostic approach to phosphopenic rickets";
var content_f28_51_29502=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 634px\">",
"   <div class=\"ttl\">",
"    Diagnostic approach to phosphopenic rickets",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 614px; height: 456px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TRP: total reabsorption of phosphorus; TmP/GFR: maximal tubular reabsorption of phosphorus per glomerular filtration rate; 1,25 (OH)",
"     <sub>",
"      2",
"     </sub>",
"     vitamin D: 1,25 dihydroxyvitamin D (calcitriol).",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_51_29502=[""].join("\n");
var outline_f28_51_29502=null;
var title_f28_51_29503="Duplex collecting system";
var content_f28_51_29503=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left duplex collecting system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tulin Ozcan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_51_29503=[""].join("\n");
var outline_f28_51_29503=null;
